antitubercular agent - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	antitubercular agent	go back to main search page
Accession:	CHEBI:33231	browse the term
Definition:	A substance that kills or slows the growth of Mycobacterium tuberculosis and is used in the treatment of tuberculosis.
Synonyms:	related_synonym:	antitubercular; antitubercular agents; antitubercular drug; antitubercular drugs; tuberculostatic agent

show annotations for term's descendants Sort by:
Rat (605) Mouse (613) Human (635) Chinchilla (0) Bonobo (0) Dog (2) Squirrel (0) Pig (1) Green Monkey (0) Naked Mole-rat (0) All
Genes (613)

4-aminosalicylic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

bone morphogenetic protein 6

increases expression

Aminosalicylic Acid results in increased expression of BMP6 mRNA

NCBI chr13:38,529,098...38,684,283
Ensembl chr13:38,529,083...38,684,278

G

C-X-C motif chemokine ligand 15

increases expression

Aminosalicylic Acid results in increased expression of CXCL8 mRNA

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

epiregulin

increases expression

Aminosalicylic Acid results in increased expression of EREG mRNA

NCBI chr 5:91,222,476...91,241,508
Ensembl chr 5:91,222,481...91,241,505

G

interleukin 24

increases expression

Aminosalicylic Acid results in increased expression of IL24 mRNA

NCBI chr 1:130,809,801...130,815,153
Ensembl chr 1:130,809,811...130,815,191

G

met proto-oncogene

increases expression

Aminosalicylic Acid results in increased expression of MET mRNA

NCBI chr 6:17,463,351...17,573,979
Ensembl chr 6:17,463,799...17,573,979

G

N-acetyl transferase 1

increases acetylation

NAT1 protein results in increased acetylation of Aminosalicylic Acid

PMID:15627487 PMID:16003948

NCBI chr 8:67,943,620...67,945,183
Ensembl chr 8:67,933,573...67,944,756

G

N-acetyltransferase 2 (arylamine N-acetyltransferase)

multiple interactions

[Peroxynitrous Acid results in decreased activity of NAT2 protein] which results in decreased acetylation of Aminosalicylic Acid

NCBI chr 8:67,947,527...67,955,296
Ensembl chr 8:67,947,510...67,955,236

G

phosphotyrosine interaction domain containing 1

increases expression

Aminosalicylic Acid results in increased expression of PID1 mRNA

NCBI chr 1:84,014,014...84,317,550
Ensembl chr 1:84,014,017...84,341,901

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 11

increases expression

Aminosalicylic Acid results in increased expression of SLC7A11 mRNA

NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063

G

secretory leukocyte peptidase inhibitor

increases expression

Aminosalicylic Acid results in increased expression of SLPI mRNA

NCBI chr 2:164,195,990...164,231,086
Ensembl chr 2:164,195,990...164,231,015

D-cycloserine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family B member 1A

multiple interactions

Cycloserine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

DNA-damage inducible transcript 3

multiple interactions

Cycloserine inhibits the reaction [resveratrol results in increased expression of DDIT3 protein]

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

early growth response 1

increases expression

Cycloserine results in increased expression of EGR1 protein

NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037

G

FBJ osteosarcoma oncogene

multiple interactions

Cycloserine promotes the reaction [Clozapine results in increased expression of FOS mRNA]

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

homer scaffolding protein 1

multiple interactions

Cycloserine inhibits the reaction [Clozapine results in increased expression of HOMER1 mRNA]; Cycloserine inhibits the reaction [Haloperidol results in increased expression of HOMER1 mRNA]

NCBI chr13:93,440,265...93,549,471
Ensembl chr13:93,436,143...93,541,637

G

mitogen-activated protein kinase 1

multiple interactions

Cycloserine inhibits the reaction [Dronabinol results in increased activity of MAPK1 protein]

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions

Cycloserine inhibits the reaction [Dronabinol results in increased activity of MAPK3 protein]

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

poly (ADP-ribose) polymerase family, member 1

multiple interactions

Cycloserine inhibits the reaction [resveratrol results in increased cleavage of PARP1 protein]

NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819

ethambutol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family B member 11

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

ATP-binding cassette, sub-family member 2

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

G

angiotensin converting enzyme 2

increases expression

Ethambutol results in increased expression of ACE2 mRNA

NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein

NCBI chr X:141,100,989...141,173,792
Ensembl chr X:141,100,989...141,173,531

G

bone morphogenetic protein 6

decreases expression

Ethambutol results in decreased expression of BMP6 mRNA

NCBI chr13:38,529,098...38,684,283
Ensembl chr13:38,529,083...38,684,278

G

caspase 3

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

catalase

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein; [isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in decreased activity of CAT protein

PMID:34118364 PMID:36878459

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

C-C motif chemokine ligand 2

affects expression

Ethambutol affects the expression of CCL2 mRNA

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 5

affects expression

Ethambutol affects the expression of CCL5 protein

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

G

cathepsin D

multiple interactions

Ethambutol results in increased expression of and affects the localization of CTSD protein; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Ethambutol results in increased expression of and affects the localization of CTSD protein]

NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775

G

C-X-C motif chemokine ligand 15

increases expression

Ethambutol results in increased expression of CXCL8 mRNA

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases activity

Ethambutol results in decreased activity of CYP1A2 protein

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 2, subfamily c, polypeptide 38

decreases activity

Ethambutol results in decreased activity of CYP2C19 protein

NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519

G

cytochrome P450, family 2, subfamily d, polypeptide 22

decreases activity

Ethambutol results in decreased activity of CYP2D6 protein

NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity
increases expression
multiple interactions

Ethambutol results in decreased activity of CYP2E1 protein
Ethambutol results in increased expression of CYP2E1 mRNA
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Ethambutol results in increased expression of and results in increased activity of CYP2E1 protein; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]

PMID:24910189 PMID:27334974 PMID:27919644

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

cytochrome P450, family 7, subfamily a, polypeptide 1

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein

NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633

G

glutamic pyruvic transaminase, soluble

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

PMID:35835356 PMID:36878459

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

glutathione peroxidase 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]

NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273

G

granzyme B

increases secretion

Ethambutol results in increased secretion of GZMB protein

NCBI chr14:56,496,293...56,499,791
Ensembl chr14:56,496,295...56,499,717

G

hypoxia inducible factor 1, alpha subunit

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304

G

interferon gamma

increases secretion

Ethambutol results in increased secretion of IFNG protein

NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797

G

interleukin 10

decreases expression

Ethambutol results in decreased expression of IL10 protein

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 13

increases secretion

Ethambutol results in increased secretion of IL13 protein

NCBI chr11:53,522,150...53,525,529
Ensembl chr11:53,522,151...53,525,529

G

interleukin 1 alpha

increases expression

Ethambutol results in increased expression of IL1A mRNA

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

interleukin 1 beta

decreases expression

Ethambutol results in decreased expression of IL1B mRNA

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

decreases expression

Ethambutol results in decreased expression of IL6 protein

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

lysosomal-associated membrane protein 2

increases expression
multiple interactions

Ethambutol results in increased expression of LAMP2 protein
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Ethambutol results in increased expression of LAMP2 protein]

NCBI chr X:37,488,524...37,545,337
Ensembl chr X:37,490,234...37,545,331

G

leptin

decreases expression

Ethambutol results in decreased expression of LEP protein

NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876

G

met proto-oncogene

increases expression

Ethambutol results in increased expression of MET mRNA

NCBI chr 6:17,463,351...17,573,979
Ensembl chr 6:17,463,799...17,573,979

G

myeloperoxidase

multiple interactions

[efavirenz co-treated with Lamivudine co-treated with Tenofovir] promotes the reaction [[isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein]; [isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4

NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447

G

phosphotyrosine interaction domain containing 1

increases expression

Ethambutol results in increased expression of PID1 mRNA

NCBI chr 1:84,014,014...84,317,550
Ensembl chr 1:84,014,017...84,341,901

G

solute carrier family 10 (sodium/bile acid cotransporter family), member 1

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1

NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 11

increases expression
multiple interactions

Ethambutol results in increased expression of SLC7A11 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]

PMID:32816093 PMID:36878459

NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063

G

secretory leukocyte peptidase inhibitor

increases expression

Ethambutol results in increased expression of SLPI mRNA

NCBI chr 2:164,195,990...164,231,086
Ensembl chr 2:164,195,990...164,231,015

ethionamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin converting enzyme 2

decreases expression

Ethionamide results in decreased expression of ACE2 mRNA

NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416

G

C-C motif chemokine ligand 2

increases expression

Ethionamide results in increased expression of CCL2 mRNA; Ethionamide results in increased expression of CCL2 protein

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 5

affects expression

Ethionamide affects the expression of CCL5 protein

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

G

C-X-C motif chemokine ligand 10

decreases expression

Ethionamide results in decreased expression of CXCL10 protein

NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748

G

flavin containing monooxygenase 2

increases oxidation

FMO2 protein results in increased oxidation of Ethionamide

NCBI chr 1:162,701,886...162,726,327
Ensembl chr 1:162,701,886...162,726,295

G

glutamate-cysteine ligase, modifier subunit

multiple interactions

Ethionamide inhibits the reaction [arsenic trioxide results in increased expression of GCLM mRNA]

NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381

G

heme oxygenase 1

multiple interactions

Ethionamide inhibits the reaction [arsenic trioxide results in increased expression of HMOX1 mRNA]

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

interleukin 10

decreases expression

Ethionamide results in decreased expression of IL10 protein

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 12b

increases expression

Ethionamide results in increased expression of IL12B protein

NCBI chr11:44,290,890...44,305,504
Ensembl chr11:44,290,890...44,304,860

G

interleukin 1 alpha

increases expression

Ethionamide results in increased expression of IL1A protein

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

interleukin 1 beta

increases expression
affects expression

Ethionamide results in increased expression of IL1B mRNA
Ethionamide affects the expression of IL1B protein

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

decreases expression

Ethionamide results in decreased expression of IL6 protein

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

kelch-like ECH-associated protein 1

multiple interactions

KEAP1 mRNA inhibits the reaction [Ethionamide results in increased susceptibility to arsenic trioxide]

NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657

G

leptin

decreases expression

Ethionamide results in decreased expression of LEP protein

NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876

G

nuclear factor, erythroid derived 2, like 2

multiple interactions

NFE2L2 mRNA promotes the reaction [Ethionamide results in increased susceptibility to arsenic trioxide]

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

sulfiredoxin 1 homolog (S. cerevisiae)

multiple interactions

Ethionamide inhibits the reaction [arsenic trioxide results in increased expression of SRXN1 mRNA]

NCBI chr 2:151,946,738...151,953,296
Ensembl chr 2:151,947,436...151,953,296

G

tumor necrosis factor

increases expression

Ethionamide results in increased expression of TNF protein

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

vascular endothelial growth factor A

increases expression

Ethionamide results in increased expression of VEGFA protein

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

isoniazide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

increases expression

Isoniazid results in increased expression of A2M mRNA

NCBI chr 6:121,612,920...121,656,197
Ensembl chr 6:121,612,335...121,656,186

G

ATP-binding cassette, sub-family B member 11

multiple interactions
decreases expression

[Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of ABCB11 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of ABCB11 mRNA]
Isoniazid results in decreased expression of ABCB11 protein
[Rifampin co-treated with Isoniazid] results in decreased expression of ABCB11 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein

PMID:25331106 PMID:25886055 PMID:32673658 PMID:35835356

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

ATP-binding cassette, sub-family C member 1

increases expression

Isoniazid results in increased expression of ABCC1 mRNA

NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601

G

ATP-binding cassette, sub-family member 2

multiple interactions
decreases expression

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein; [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of ABCC2 mRNA
Isoniazid results in decreased expression of ABCC2 mRNA

PMID:25331106 PMID:32673658 PMID:35835356

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

G

ATP-binding cassette, sub-family C member 3

multiple interactions
decreases expression

[Lipopolysaccharides co-treated with Isoniazid] results in increased expression of ABCC3 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of ABCC3 mRNA]

PMID:25331106 PMID:32673658

NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823

G

ATP-binding cassette, sub-family C member 4

decreases expression

Isoniazid results in decreased expression of ABCC4 mRNA

NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631

G

ATP-binding cassette, sub-family C member 6

decreases expression

Isoniazid results in decreased expression of ABCC6 mRNA

NCBI chr 7:45,625,804...45,679,915
Ensembl chr 7:45,616,979...45,679,726

G

angiotensin converting enzyme 2

decreases expression

Isoniazid results in decreased expression of ACE2 mRNA

NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein

NCBI chr X:141,100,989...141,173,792
Ensembl chr X:141,100,989...141,173,531

G

alpha fetoprotein

decreases expression

Isoniazid results in decreased expression of AFP mRNA

NCBI chr 5:90,638,573...90,656,766
Ensembl chr 5:90,638,596...90,656,766

G

1-acylglycerol-3-phosphate O-acyltransferase 3

multiple interactions
increases expression

[Zidovudine co-treated with Isoniazid] results in increased expression of AGPAT3 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in increased expression of AGPAT3 mRNA]
Isoniazid results in increased expression of AGPAT3 mRNA

NCBI chr10:78,105,008...78,188,335
Ensembl chr10:78,105,012...78,188,323

G

aldo-keto reductase family 1, member B10

increases expression

Isoniazid results in increased expression of AKR1B10 mRNA

NCBI chr 6:34,361,182...34,373,884
Ensembl chr 6:34,361,153...34,373,885

G

aminolevulinic acid synthase 1

increases expression

Isoniazid results in increased expression of ALAS1 protein

PMID:27438535 PMID:30517741

NCBI chr 9:106,110,654...106,125,153
Ensembl chr 9:106,110,654...106,125,853

G

albumin

affects binding

Isoniazid binds to ALB protein

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

alkaline phosphatase, liver/bone/kidney

increases activity
multiple interactions

Isoniazid results in increased activity of ALPL protein
[Rifampin co-treated with Isoniazid] results in increased activity of ALPL protein

NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695

G

apolipoprotein A-IV

affects response to substance

APOA4 affects the susceptibility to Isoniazid

NCBI chr 9:46,152,142...46,154,756
Ensembl chr 9:46,151,994...46,154,757

G

apolipoprotein A-V

decreases expression
multiple interactions

Isoniazid results in decreased expression of APOA5 mRNA
[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA]

NCBI chr 9:46,179,906...46,183,219
Ensembl chr 9:46,179,931...46,183,217

G

amyloid beta precursor protein

increases expression

Isoniazid results in increased expression of APP mRNA

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

G

argininosuccinate lyase

increases activity
multiple interactions

Isoniazid results in increased activity of ASL protein
[Isoniazid co-treated with Zidovudine] results in increased activity of ASL protein; silybin inhibits the reaction [[Isoniazid co-treated with Zidovudine] results in increased activity of ASL protein]

NCBI chr 5:130,040,099...130,053,222
Ensembl chr 5:130,040,099...130,058,088

G

ATPase, Na+/K+ transporting, beta 1 polypeptide

increases expression

Isoniazid results in increased expression of ATP1B1 mRNA

NCBI chr 1:164,264,668...164,285,924
Ensembl chr 1:164,264,678...164,285,924

G

ATP synthase F1 subunit beta

affects expression

Isoniazid affects the expression of ATP5F1B mRNA

NCBI chr10:127,919,176...127,926,257
Ensembl chr10:127,919,142...127,926,260

G

ATP synthase membrane subunit c locus 1

affects expression

Isoniazid affects the expression of ATP5MC1 mRNA

NCBI chr11:95,963,619...95,966,520
Ensembl chr11:95,959,678...95,966,496

G

ATP synthase membrane subunit c locus 3

affects expression

Isoniazid affects the expression of ATP5MC3 mRNA

NCBI chr 2:73,738,791...73,742,793
Ensembl chr 2:73,738,791...73,741,670

G

ATP synthase peripheral stalk-membrane subunit b

affects expression

Isoniazid affects the expression of ATP5PB mRNA

NCBI chr 3:105,850,014...105,866,579
Ensembl chr 3:105,850,014...105,867,415

G

ATP synthase peripheral stalk subunit F6

affects expression

Isoniazid affects the expression of ATP5PF mRNA

NCBI chr16:84,624,754...84,632,495
Ensembl chr16:84,624,754...84,632,513

G

BCL2-associated X protein

multiple interactions
increases expression
affects expression

[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein]
Isoniazid results in increased expression of BAX protein
Quercetin inhibits the reaction [Isoniazid results in increased expression of BAX protein]
chrysin inhibits the reaction [Isoniazid results in increased expression of BAX protein]
Isoniazid results in increased expression of BAX mRNA
Isoniazid affects the expression of BAX protein

PMID:20433247 PMID:21419764 PMID:31332904 PMID:33121995 PMID:33771660

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

gamma-butyrobetaine hydroxylase 1

increases expression

Isoniazid results in increased expression of BBOX1 mRNA

NCBI chr 2:110,094,401...110,145,158
Ensembl chr 2:110,093,042...110,144,905

G

B cell leukemia/lymphoma 2

multiple interactions
decreases expression

[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein]
Isoniazid results in decreased expression of BCL2 protein
Quercetin inhibits the reaction [Isoniazid results in decreased expression of BCL2 protein]
Isoniazid results in decreased expression of BCL2 mRNA

PMID:20433247 PMID:21419764 PMID:31332904 PMID:33771660

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

caspase 3

multiple interactions
increases cleavage
increases expression
increases activity

[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]
acadesine promotes the reaction [Isoniazid results in increased cleavage of CASP3 protein]; Quercetin inhibits the reaction [Isoniazid results in increased cleavage of CASP3 protein]
Isoniazid results in increased expression of CASP3 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3
Isoniazid results in increased activity of CASP3 protein

PMID:20433247 PMID:21419764 PMID:23764483 PMID:28556920 PMID:31332904 More...

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 9

increases cleavage
increases activity
multiple interactions

Isoniazid results in increased cleavage of CASP9 protein
Isoniazid results in increased activity of CASP9 protein
Quercetin inhibits the reaction [Isoniazid results in increased cleavage of CASP9 protein]

PMID:20433247 PMID:31332904

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

G

calcium-sensing receptor

affects expression

Isoniazid affects the expression of CASR mRNA

NCBI chr16:36,310,947...36,382,605
Ensembl chr16:36,314,058...36,382,503

G

catalase

decreases activity
multiple interactions

Isoniazid results in decreased activity of CAT protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein; chrysin inhibits the reaction [Isoniazid results in decreased activity of CAT protein]

PMID:20433247 PMID:33121995 PMID:33771660 PMID:36878459

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

C-C motif chemokine receptor 2

decreases expression

Isoniazid results in decreased expression of CCR2 mRNA

NCBI chr 9:123,901,954...123,913,594
Ensembl chr 9:123,901,987...123,913,594

G

CCAAT/enhancer binding protein alpha

decreases expression

Isoniazid results in decreased expression of CEBPA mRNA; Isoniazid results in decreased expression of CEBPA protein

NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353

G

CCAAT/enhancer binding protein beta

decreases expression

Isoniazid results in decreased expression of CEBPB protein

NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338

G

CCAAT/enhancer binding protein delta

decreases expression

Isoniazid results in decreased expression of CEBPD mRNA; Isoniazid results in decreased expression of CEBPD protein

NCBI chr16:15,705,150...15,707,409
Ensembl chr16:15,705,150...15,708,895

G

choline phosphotransferase 1

affects response to substance

CHPT1 affects the susceptibility to Isoniazid

NCBI chr10:88,305,376...88,339,855
Ensembl chr10:88,288,607...88,339,935

G

claudin 2

increases expression

Isoniazid results in increased expression of CLDN2 mRNA

NCBI chr X:138,701,552...138,712,135
Ensembl chr X:138,701,577...138,712,135

G

cytochrome c oxidase assembly protein 11, copper chaperone

affects expression

Isoniazid affects the expression of COX11 mRNA

NCBI chr11:90,529,010...90,536,803
Ensembl chr11:90,528,999...90,535,757

G

cytochrome c oxidase assembly protein 17, copper chaperone

affects expression

Isoniazid affects the expression of COX17 mRNA

NCBI chr16:38,167,332...38,173,125
Ensembl chr16:38,167,353...38,182,659

G

cytochrome c oxidase subunit 5B

affects expression

Isoniazid affects the expression of COX5B mRNA

NCBI chr 1:36,730,568...36,732,469
Ensembl chr 1:36,730,530...36,732,762

G

cytochrome c oxidase subunit 6A1

affects expression

Isoniazid affects the expression of COX6A1 mRNA

NCBI chr 5:115,483,711...115,487,017
Ensembl chr 5:115,483,701...115,487,040

G

cytochrome c oxidase, subunit 6B1

affects expression

Isoniazid affects the expression of COX6B1 mRNA

NCBI chr 7:30,316,396...30,325,539
Ensembl chr 7:30,316,286...30,325,576

G

cytochrome c oxidase subunit 7A2

affects expression

Isoniazid affects the expression of COX7A2 mRNA

NCBI chr 9:79,662,523...79,667,135
Ensembl chr 9:79,662,643...79,667,160

G

carnitine palmitoyltransferase 1a, liver

affects expression

Isoniazid affects the expression of CPT1A mRNA

NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733

G

C-X-C motif chemokine ligand 10

increases secretion

Isoniazid results in increased secretion of CXCL10 protein

NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748

G

C-X-C motif chemokine ligand 15

multiple interactions

[Isoniazid co-treated with lipopolysaccharide, E. coli O26-B6] results in decreased expression of CXCL8 mRNA

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

cytochrome b5 type A (microsomal)

multiple interactions
decreases expression

[Zidovudine co-treated with Isoniazid] results in decreased expression of CYB5A mRNA; Silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of CYB5A mRNA]
Isoniazid results in decreased expression of CYB5A mRNA

NCBI chr18:84,869,463...84,897,996
Ensembl chr18:84,856,829...84,897,996

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA]; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein]

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 27, subfamily a, polypeptide 1

increases expression

Isoniazid results in increased expression of CYP27A1 mRNA

NCBI chr 1:74,752,311...74,777,056
Ensembl chr 1:74,752,733...74,777,051

G

cytochrome P450, family 2, subfamily c, polypeptide 29

decreases activity
multiple interactions

Isoniazid results in decreased activity of CYP2C8 protein
torsemide inhibits the reaction [Isoniazid results in decreased activity of CYP2C8 protein]

NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157

G

cytochrome P450, family 2, subfamily e, polypeptide 1

affects response to substance
increases metabolic processing
multiple interactions
increases expression
increases activity
increases response to substance
decreases activity

CYP2E1 gene polymorphism affects the susceptibility to Isoniazid; CYP2E1 gene SNP affects the susceptibility to Isoniazid
CYP2E1 protein results in increased metabolism of Isoniazid
2-(allylthio)pyrazine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Isoniazid results in increased activity of CYP2E1 protein] which results in increased metabolism of 4-dichlorobenzene; [Isoniazid results in increased expression of CYP2E1] which results in increased metabolism of Acetaminophen; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; diphenyleneiodonium inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]; Isoniazid inhibits the reaction [CYP2E1 protein results in increased reduction of Tirapazamine]; Isoniazid results in increased expression of and results in increased activity of CYP2E1 protein; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; NADP promotes the reaction [Isoniazid results in decreased activity of CYP2E1 protein]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]; Thiram inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]; Tiopronin inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]
Isoniazid results in increased expression of CYP2E1; Isoniazid results in increased expression of CYP2E1 mRNA; Isoniazid results in increased expression of CYP2E1 protein
[Isoniazid co-treated with Rifampin co-treated with dendrobine] results in decreased expression of CYP2E1 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP2E1 mRNA; Berberine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 mRNA]; NADP promotes the reaction [Isoniazid results in decreased activity of CYP2E1 protein]
GSTM1 protein inhibits the reaction [CYP2E1 protein results in increased susceptibility to Isoniazid]; NADP promotes the reaction [Isoniazid results in decreased activity of CYP2E1 protein]

PMID:3113478 PMID:7710944 PMID:8074729 PMID:9051121 PMID:9065729 More...

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

cytochrome P450, family 7, subfamily a, polypeptide 1

multiple interactions
increases expression

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein; [Lipopolysaccharides co-treated with Isoniazid] results in increased expression of CYP7A1 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in increased expression of CYP7A1 mRNA]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein; [Isoniazid co-treated with Vitamin B 6] results in increased expression of CYP7A1 mRNA

PMID:25331106 PMID:32673658 PMID:35835356

NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633

G

DNA-damage inducible transcript 3

increases expression
decreases expression

Isoniazid results in increased expression of DDIT3 mRNA
Isoniazid results in decreased expression of DDIT3 mRNA

PMID:12883083 PMID:30008028

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

DEPP1 autophagy regulator

increases expression

Isoniazid results in increased expression of DEPP1 mRNA

NCBI chr 6:116,627,645...116,629,808
Ensembl chr 6:116,627,570...116,629,755

G

eosinophil peroxidase

increases oxidation
multiple interactions

EPX protein results in increased oxidation of Isoniazid
[EPX protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of isonicotinyl-NAD

NCBI chr11:87,754,824...87,766,362
Ensembl chr11:87,754,826...87,766,362

G

ferrochelatase

decreases expression

Isoniazid results in decreased expression of FECH protein

PMID:27438535 PMID:30517741

NCBI chr18:64,589,613...64,622,169
Ensembl chr18:64,585,985...64,623,322

G

glucose-6-phosphate dehydrogenase X-linked

decreases activity

Isoniazid results in decreased activity of G6PD protein

NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800

G

growth arrest and DNA-damage-inducible 45 alpha

decreases expression

Isoniazid results in decreased expression of GADD45A mRNA

NCBI chr 6:67,012,080...67,014,391
Ensembl chr 6:67,012,080...67,014,441

G

glyceraldehyde-3-phosphate dehydrogenase

increases expression

Isoniazid results in increased expression of GAPDH mRNA

NCBI chr 6:125,138,812...125,143,450
Ensembl chr 6:125,138,678...125,143,430

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions
decreases expression
increases expression

Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of GCLC mRNA]
Isoniazid results in decreased expression of GCLC mRNA
Isoniazid results in increased expression of GCLC mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of GCLC mRNA]

PMID:24128855 PMID:33121995 PMID:33771660

NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767

G

glutamate-cysteine ligase, modifier subunit

decreases expression
increases expression
multiple interactions

Isoniazid results in decreased expression of GCLM mRNA
Isoniazid results in increased expression of GCLM mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of GCLM mRNA]

PMID:30008028 PMID:33121995 PMID:33771660

NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381

G

glial fibrillary acidic protein

multiple interactions
increases expression

chrysin inhibits the reaction [Isoniazid results in increased expression of GFAP mRNA]; chrysin inhibits the reaction [Isoniazid results in increased expression of GFAP protein]
Isoniazid results in increased expression of GFAP mRNA; Isoniazid results in increased expression of GFAP protein

NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738

G

gamma-glutamyltransferase 1

multiple interactions

[Lipopolysaccharides co-treated with Isoniazid] results in increased activity of GGT1 protein

NCBI chr10:75,396,910...75,422,027
Ensembl chr10:75,397,438...75,422,034

G

glutamic-oxaloacetic transaminase 1, soluble

multiple interactions
increases activity

[Rifampin co-treated with Isoniazid] results in increased activity of GOT1 protein
Isoniazid results in increased activity of GOT1 protein

NCBI chr19:43,488,191...43,514,743
Ensembl chr19:43,488,191...43,513,044

G

glutamic pyruvic transaminase, soluble

increases activity
multiple interactions
increases expression

Isoniazid results in increased activity of GPT protein
[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein; [Rifampin co-treated with Isoniazid] results in increased activity of GPT protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein]
Quercetin inhibits the reaction [Isoniazid results in increased expression of GPT protein]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; [Lipopolysaccharides co-treated with Isoniazid] results in increased activity of GPT protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]; Isoniazid promotes the reaction [Zidovudine results in increased activity of GPT protein]; Silybin inhibits the reaction [Isoniazid promotes the reaction [Zidovudine results in increased activity of GPT protein]]

PMID:25331106 PMID:25886055 PMID:28619387 PMID:31332904 PMID:32633153 More...

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

glutathione peroxidase 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]

NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273

G

glutathione S-transferase, alpha 2 (Yc2)

increases expression

Isoniazid results in increased expression of GSTA2 mRNA

NCBI chr 9:78,238,300...78,254,474
Ensembl chr 9:78,238,300...78,263,070

G

glutathione S-transferase, mu 1

multiple interactions
decreases response to substance

GSTM1 protein inhibits the reaction [CYP2E1 protein results in increased susceptibility to Isoniazid]
GSTM1 protein results in decreased susceptibility to Isoniazid

NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289

G

glutathione S-transferase, pi 1

decreases expression

Isoniazid results in decreased expression of GSTP1 mRNA

NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985

G

glutathione S-transferase, theta 1

multiple interactions

GSTT1 gene polymorphism affects the susceptibility to [Isoniazid co-treated with Rifampin]; GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide]

PMID:18397238 PMID:20485159

NCBI chr10:75,619,647...75,634,418
Ensembl chr10:75,619,647...75,634,418

G

hepatitis A virus cellular receptor 1

affects expression

Isoniazid affects the expression of HAVCR1 mRNA

NCBI chr11:46,630,644...46,670,405
Ensembl chr11:46,625,907...46,670,405

G

hepatocyte growth factor

multiple interactions

HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased abundance of Reactive Oxygen Species]; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]

NCBI chr 5:16,758,493...16,827,448
Ensembl chr 5:16,758,493...16,825,150

G

hypoxia inducible factor 1, alpha subunit

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304

G

heme oxygenase 1

multiple interactions
decreases expression
increases expression

Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA]
Isoniazid results in decreased expression of HMOX1 mRNA
Isoniazid results in increased expression of HMOX1 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of HMOX1 mRNA]

PMID:24128855 PMID:33121995 PMID:33771660

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

heme oxygenase 2

increases expression

Isoniazid results in increased expression of HMOX2 mRNA

NCBI chr16:4,544,225...4,584,606
Ensembl chr16:4,544,225...4,584,606

G

hypoxanthine phosphoribosyltransferase 1

increases expression

Isoniazid results in increased expression of HPRT1 mRNA

NCBI chr X:52,076,955...52,110,537
Ensembl chr X:52,077,014...52,110,536

G

interferon gamma

increases secretion

Isoniazid results in increased secretion of IFNG protein

NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797

G

interleukin 10

increases secretion

Isoniazid results in increased secretion of IL10 protein

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 12a

increases secretion

Isoniazid results in increased secretion of IL12A protein

NCBI chr 3:68,597,977...68,605,881
Ensembl chr 3:68,597,977...68,605,880

G

interleukin 12b

increases secretion

Isoniazid results in increased secretion of IL12B protein

NCBI chr11:44,290,890...44,305,504
Ensembl chr11:44,290,890...44,304,860

G

interleukin 17A

increases secretion

Isoniazid results in increased secretion of IL17A protein

NCBI chr 1:20,801,129...20,804,720
Ensembl chr 1:20,801,129...20,804,720

G

interleukin 1 alpha

increases secretion
increases expression

Isoniazid results in increased secretion of IL1A protein
Isoniazid results in increased expression of IL1A mRNA

PMID:28444390 PMID:32816093

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

interleukin 1 beta

increases secretion
increases expression
multiple interactions

Isoniazid results in increased secretion of IL1B protein
Isoniazid results in increased expression of IL1B mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of IL1B mRNA]

PMID:28444390 PMID:32816093 PMID:33121995

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 2

multiple interactions

[Isoniazid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA

NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108

G

interleukin 24

increases expression

Isoniazid results in increased expression of IL24 mRNA

NCBI chr 1:130,809,801...130,815,153
Ensembl chr 1:130,809,811...130,815,191

G

interleukin 6

increases expression
increases secretion
multiple interactions

Isoniazid results in increased expression of IL6 protein
Isoniazid results in increased secretion of IL6 protein
Isoniazid results in increased expression of IL6 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of IL6 mRNA]

PMID:19575532 PMID:28444390 PMID:33121995

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

inhibin beta-E

increases expression

Isoniazid results in increased expression of INHBE mRNA

NCBI chr10:127,185,271...127,187,717
Ensembl chr10:127,184,726...127,190,280

G

IZUMO1 receptor, JUNO

decreases expression

Isoniazid results in decreased expression of IZUMO1R protein

NCBI chr 9:14,797,110...14,815,247
Ensembl chr 9:14,797,110...14,815,245

G

kelch-like ECH-associated protein 1

decreases expression

Isoniazid results in decreased expression of KEAP1 mRNA

NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657

G

lysosomal-associated membrane protein 1

affects response to substance

LAMP1 affects the susceptibility to Isoniazid

NCBI chr 8:13,209,161...13,225,338
Ensembl chr 8:13,209,161...13,225,338

G

lipocalin 2

increases expression

Isoniazid results in increased expression of LCN2 mRNA

NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264

G

microtubule-associated protein 2

affects expression

Isoniazid affects the expression of MAP2 mRNA

NCBI chr 1:66,214,337...66,481,742
Ensembl chr 1:66,214,432...66,481,742

G

mitogen-activated protein kinase 1

multiple interactions
decreases phosphorylation

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK1 protein]]; Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK1 protein]

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions
decreases phosphorylation

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK3 protein]]; Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK3 protein]

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

microsomal glutathione S-transferase 1

increases expression

Isoniazid results in increased expression of MGST1 mRNA

NCBI chr 6:138,117,525...138,133,753
Ensembl chr 6:138,117,314...138,133,753

G

microRNA 106b

decreases expression

Isoniazide decreased expression of miR106b miRNA in the liver

RGD

NCBI chr 5:138,163,999...138,164,080
Ensembl chr 5:138,163,999...138,164,080

G

microRNA 186

multiple interactions

[Isoniazid co-treated with Rifampin] results in increased expression of MIR186 mRNA

NCBI chr 3:157,249,916...157,249,986
Ensembl chr 3:157,249,916...157,249,986

G

microRNA 295

multiple interactions

[Isoniazid co-treated with Rifampin] results in increased expression of MIR295 mRNA; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of MIR295 mRNA]

NCBI chr 7:3,269,447...3,269,515
Ensembl chr 7:3,269,447...3,269,515

G

myeloperoxidase

multiple interactions
increases oxidation

[[MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of Free Radicals] which results in increased chemical synthesis of isonicotinyl-NAD; [MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of Free Radicals; [MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of isonicotinyl-NAD

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

cytochrome c oxidase III, mitochondrial

increases expression

Isoniazid results in increased expression of COX3 mRNA

NCBI chr MT:8,607...9,390
Ensembl chr MT:8,607...9,390

G

mucin 1, transmembrane

increases expression

Isoniazid results in increased expression of MUC1 mRNA

NCBI chr 3:89,136,363...89,140,688
Ensembl chr 3:89,136,364...89,140,688

G

N-acetyltransferase 2 (arylamine N-acetyltransferase)

increases acetylation
affects acetylation
decreases expression
multiple interactions
decreases acetylation
increases metabolic processing
affects metabolic processing
affects response to substance

NAT2 protein polymorphism results in increased acetylation of Isoniazid; NAT2 protein results in increased acetylation of Isoniazid
NAT2 protein polymorphism affects the acetylation of Isoniazid
Isoniazid results in decreased expression of NAT2 mRNA
[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA]
[NAT2 gene polymorphism results in decreased acetylation of Isoniazid] which results in decreased abundance of acetylisoniazid; [NAT2 gene polymorphism results in decreased metabolism of Isoniazid] which results in increased abundance of hydrazine
NAT2 protein results in increased metabolism of Isoniazid
NAT2 protein affects the metabolism of Isoniazid; NAT2 protein polymorphism affects the metabolism of Isoniazid
NAT2 gene polymorphism affects the susceptibility to Isoniazid; NAT2 gene SNP affects the susceptibility to Isoniazid

PMID:11379777 PMID:11915035 PMID:15546075 PMID:15565348 PMID:15618686 More...

NCBI chr 8:67,947,527...67,955,296
Ensembl chr 8:67,947,510...67,955,236

G

NADH:ubiquinone oxidoreductase subunit A1

affects expression

Isoniazid affects the expression of NDUFA1 mRNA

NCBI chr X:36,451,241...36,454,891
Ensembl chr X:36,451,241...36,454,816

G

NADH:ubiquinone oxidoreductase subunit A10

affects expression

Isoniazid affects the expression of NDUFA10 mRNA

NCBI chr 1:92,367,208...92,401,547
Ensembl chr 1:92,366,732...92,401,582

G

NADH:ubiquinone oxidoreductase subunit A12

affects expression

Isoniazid affects the expression of NDUFA12 mRNA

NCBI chr10:94,034,897...94,057,302
Ensembl chr10:94,034,582...94,057,305

G

NADH:ubiquinone oxidoreductase subunit A13

affects expression

Isoniazid affects the expression of NDUFA13 mRNA

NCBI chr 8:70,346,813...70,355,208
Ensembl chr 8:70,346,830...70,355,208

G

Ndufa4, mitochondrial complex associated

affects expression

Isoniazid affects the expression of NDUFA4 mRNA

NCBI chr 6:11,900,371...11,907,449
Ensembl chr 6:11,900,291...11,907,496

G

NADH:ubiquinone oxidoreductase subunit A5

affects expression

Isoniazid affects the expression of NDUFA5 mRNA

NCBI chr 6:24,518,661...24,527,689
Ensembl chr 6:24,518,665...24,528,012

G

NADH:ubiquinone oxidoreductase subunit A8

affects expression

Isoniazid affects the expression of NDUFA8 mRNA

NCBI chr 2:35,926,336...35,939,350
Ensembl chr 2:35,926,338...35,939,418

G

NADH:ubiquinone oxidoreductase subunit A9

affects expression

Isoniazid affects the expression of NDUFA9 mRNA

NCBI chr 6:126,798,826...126,826,107
Ensembl chr 6:126,798,684...126,826,099

G

NADH:ubiquinone oxidoreductase subunit AB1

affects expression

Isoniazid affects the expression of NDUFAB1 mRNA

NCBI chr 7:121,686,038...121,701,071
Ensembl chr 7:121,684,626...121,701,109

G

NADH:ubiquinone oxidoreductase subunit B10

affects expression

Isoniazid affects the expression of NDUFB10 mRNA

NCBI chr17:24,941,034...24,943,397
Ensembl chr17:24,941,034...24,943,452

G

NADH:ubiquinone oxidoreductase subunit B2

affects expression

Isoniazid affects the expression of NDUFB2 mRNA

NCBI chr 6:39,569,499...39,576,777
Ensembl chr 6:39,569,508...39,580,316

G

NADH:ubiquinone oxidoreductase subunit B3

affects expression

Isoniazid affects the expression of NDUFB3 mRNA

NCBI chr 1:58,625,556...58,635,123
Ensembl chr 1:58,625,543...58,635,123

G

NADH:ubiquinone oxidoreductase subunit B5

affects expression

Isoniazid affects the expression of NDUFB5 mRNA

NCBI chr 3:32,791,206...32,805,708
Ensembl chr 3:32,791,139...32,805,715

G

NADH:ubiquinone oxidoreductase subunit B6

affects expression

Isoniazid affects the expression of NDUFB6 mRNA

NCBI chr 4:40,270,591...40,279,421
Ensembl chr 4:40,270,591...40,279,421

G

NADH:ubiquinone oxidoreductase subunit B7

affects expression

Isoniazid affects the expression of NDUFB7 mRNA

NCBI chr 8:84,293,387...84,298,252
Ensembl chr 8:84,293,300...84,298,255

G

NADH:ubiquinone oxidoreductase core subunit S1

affects expression

Isoniazid affects the expression of NDUFS1 mRNA

NCBI chr 1:63,182,751...63,215,981
Ensembl chr 1:63,182,755...63,215,992

G

NADH:ubiquinone oxidoreductase core subunit S2

affects expression

Isoniazid affects the expression of NDUFS2 mRNA

NCBI chr 1:171,062,426...171,078,956
Ensembl chr 1:171,062,422...171,078,957

G

NADH:ubiquinone oxidoreductase core subunit S3

affects expression

Isoniazid affects the expression of NDUFS3 mRNA

NCBI chr 2:90,724,971...90,735,065
Ensembl chr 2:90,724,978...90,735,171

G

NADH:ubiquinone oxidoreductase core subunit S4

affects expression

Isoniazid affects the expression of NDUFS4 mRNA

NCBI chr13:114,424,331...114,524,630
Ensembl chr13:114,424,331...114,524,794

G

NADH:ubiquinone oxidoreductase core subunit S8

affects expression

Isoniazid affects the expression of NDUFS8 mRNA

NCBI chr19:3,958,863...3,962,774
Ensembl chr19:3,958,863...3,962,774

G

NADH:ubiquinone oxidoreductase core subunit V1

affects expression

Isoniazid affects the expression of NDUFV1 mRNA

NCBI chr19:4,057,499...4,062,755
Ensembl chr19:4,057,384...4,062,806

G

NADH:ubiquinone oxidoreductase core subunit V2

affects expression

Isoniazid affects the expression of NDUFV2 mRNA

NCBI chr17:66,385,790...66,408,554
Ensembl chr17:66,385,633...66,408,554

G

nuclear factor, erythroid derived 2, like 2

increases activity
increases expression
multiple interactions

Isoniazid results in increased activity of NFE2L2 protein
Isoniazid results in increased expression of NFE2L2 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of NFE2L2 mRNA]

PMID:30203046 PMID:33121995 PMID:33771660

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105

multiple interactions
increases expression

chrysin inhibits the reaction [Isoniazid results in increased expression of NFKB1 mRNA]

NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308

G

NAD(P)H dehydrogenase, quinone 1

multiple interactions
decreases expression
increases expression

Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]
Isoniazid results in decreased expression of NQO1 mRNA
Isoniazid results in increased expression of NQO1 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of NQO1 mRNA]

PMID:24128855 PMID:28444390 PMID:33121995 PMID:33771660

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions
decreases expression

obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of NR0B2 mRNA]
[Isoniazid co-treated with Vitamin B 6] results in decreased expression of NR0B2 mRNA

NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions
decreases expression

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4; [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of NR1H4 mRNA; [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of NR1H4 protein; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of NR1H4 mRNA]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4; [Isoniazid co-treated with Vitamin B 6] results in decreased expression of NR1H4 mRNA
isoniazide decreases expression of nr1h4 protein in rat liver

CTD
RGD

PMID:25331106 PMID:32673658 PMID:35835356 PMID:30068870

NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447

G

nuclear receptor subfamily 1, group I, member 3

increases activity

Isoniazid results in increased activity of NR1I3 protein

NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270

G

nuclear respiratory factor 1

decreases expression
multiple interactions

Isoniazid results in decreased expression of NRF1 protein
acadesine inhibits the reaction [Isoniazid results in decreased expression of NRF1 protein]

NCBI chr 6:30,047,984...30,153,462
Ensembl chr 6:30,047,987...30,153,457

G

nuclear protein transcription regulator 1

increases expression

Isoniazid results in increased expression of NUPR1 mRNA

NCBI chr 7:126,222,418...126,224,642
Ensembl chr 7:126,222,421...126,230,033

G

oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide)

affects expression

Isoniazid affects the expression of OGDH mRNA

NCBI chr11:6,241,597...6,309,094
Ensembl chr11:6,241,633...6,306,642

G

Parkinson disease (autosomal recessive, early onset) 7

affects expression

Isoniazid affects the expression of PARK7 mRNA

NCBI chr 4:150,981,590...150,994,378
Ensembl chr 4:150,981,590...150,998,894

G

phosphotyrosine interaction domain containing 1

increases expression

Isoniazid results in increased expression of PID1 mRNA

NCBI chr 1:84,014,014...84,317,550
Ensembl chr 1:84,014,017...84,341,901

G

procollagen lysine, 2-oxoglutarate 5-dioxygenase 2

increases expression

Isoniazid results in increased expression of PLOD2 mRNA

NCBI chr 9:92,421,828...92,490,481
Ensembl chr 9:92,424,276...92,490,481

G

cytochrome p450 oxidoreductase

multiple interactions
decreases expression

[Zidovudine co-treated with Isoniazid] results in decreased expression of POR mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of POR mRNA]
Isoniazid results in decreased expression of POR mRNA

NCBI chr 5:135,698,894...135,764,180
Ensembl chr 5:135,698,887...135,764,180

G

peroxisome proliferator activated receptor alpha

increases activity
multiple interactions

Isoniazid results in increased activity of PPARA protein
[Isoniazid co-treated with Rifampin] results in decreased expression of PPARA protein

PMID:30203046 PMID:36347327

NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020

G

peroxisome proliferator activated receptor gamma

decreases expression
multiple interactions

Isoniazid results in decreased expression of PPARG mRNA
[Isoniazid co-treated with Rifampin] results in decreased expression of PPARG protein
Isoniazid results in decreased expression of PPARG mRNA; Isoniazid results in decreased expression of PPARG protein

PMID:24128855 PMID:36347327

NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360

G

peroxisome proliferative activated receptor, gamma, coactivator 1 alpha

multiple interactions
decreases expression

acadesine inhibits the reaction [Isoniazid results in decreased expression of PPARGC1A protein]

NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068

G

presenilin 1

affects expression

Isoniazid affects the expression of PSEN1 mRNA

NCBI chr12:83,734,926...83,781,869
Ensembl chr12:83,734,926...83,781,973

G

prostaglandin-endoperoxide synthase 2

increases expression

Isoniazid results in increased expression of PTGS2 mRNA

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

succinate dehydrogenase complex, subunit A, flavoprotein (Fp)

affects expression

Isoniazid affects the expression of SDHA mRNA

NCBI chr13:74,470,374...74,498,359
Ensembl chr13:74,470,373...74,498,399

G

succinate dehydrogenase complex, subunit B, iron sulfur (Ip)

affects expression

Isoniazid affects the expression of SDHB mRNA

NCBI chr 4:140,688,582...140,706,509
Ensembl chr 4:140,688,514...140,706,504

G

succinate dehydrogenase complex, subunit D, integral membrane protein

affects expression

Isoniazid affects the expression of SDHD mRNA

NCBI chr 9:50,507,640...50,515,149
Ensembl chr 9:50,507,657...50,515,112

G

stratifin

decreases expression

Isoniazid results in decreased expression of SFN mRNA

NCBI chr 4:133,327,867...133,329,163
Ensembl chr 4:133,327,867...133,329,479

G

sirtuin 1

multiple interactions
decreases expression

acadesine inhibits the reaction [Isoniazid results in decreased expression of SIRT1 protein]; Quercetin inhibits the reaction [Isoniazid results in decreased expression of SIRT1 protein]

PMID:28556920 PMID:31332904

NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483

G

solute carrier family 10 (sodium/bile acid cotransporter family), member 1

multiple interactions
decreases expression

obeticholic acid promotes the reaction [Isoniazid results in decreased expression of SLC10A1 mRNA]
Isoniazid results in decreased expression of SLC10A1 protein
[Rifampin co-treated with Isoniazid] results in decreased expression of SLC10A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1

PMID:25886055 PMID:32673658 PMID:35835356

NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479

G

solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1

affects expression

Isoniazid affects the expression of SLC11A1 mRNA

NCBI chr 1:74,414,318...74,429,974
Ensembl chr 1:74,414,354...74,425,221

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 11

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]

NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 5

decreases expression

Isoniazid results in decreased expression of SLC7A5 mRNA

NCBI chr 8:122,607,885...122,634,425
Ensembl chr 8:122,607,889...122,634,433

G

solute carrier organic anion transporter family, member 1c1

decreases expression

Isoniazid results in decreased expression of SLCO1B1 mRNA

NCBI chr 6:141,470,080...141,515,903
Ensembl chr 6:141,470,094...141,515,903

G

secretory leukocyte peptidase inhibitor

increases expression

Isoniazid results in increased expression of SLPI mRNA

NCBI chr 2:164,195,990...164,231,086
Ensembl chr 2:164,195,990...164,231,015

G

superoxide dismutase 1, soluble

increases expression

Isoniazid results in increased expression of SOD1 mRNA

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

G

superoxide dismutase 2, mitochondrial

multiple interactions
affects expression

[SOD2 co-treated with CYP3A4] affects the susceptibility to Isoniazid
Isoniazid affects the expression of SOD2 mRNA

PMID:19501153 PMID:24848797

NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950

G

secreted phosphoprotein 1

affects expression
decreases expression

Isoniazid affects the expression of SPP1 mRNA
Isoniazid results in decreased expression of SPP1 mRNA

PMID:20623750 PMID:30008028

NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916

G

sulfiredoxin 1 homolog (S. cerevisiae)

increases expression

Isoniazid results in increased expression of SRXN1 mRNA

NCBI chr 2:151,946,738...151,953,296
Ensembl chr 2:151,947,436...151,953,296

G

surfeit gene 1

affects expression

Isoniazid affects the expression of SURF1 mRNA

NCBI chr 2:26,803,390...26,806,667
Ensembl chr 2:26,803,393...26,806,542

G

tumor necrosis factor

increases secretion
multiple interactions
increases expression

Isoniazid results in increased secretion of TNF protein
[Isoniazid co-treated with Zidovudine] results in increased expression of TNF protein; chrysin inhibits the reaction [Isoniazid results in increased expression of TNF protein]; Isoniazid promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Silybin inhibits the reaction [[Isoniazid co-treated with Zidovudine] results in increased expression of TNF protein]

PMID:25331106 PMID:28444390 PMID:28619387 PMID:33121995

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

thyroid peroxidase

decreases activity

Isoniazid results in decreased activity of TPO protein

NCBI chr12:30,104,658...30,182,983
Ensembl chr12:30,104,658...30,182,623

G

trafficking protein, kinesin binding 1

affects expression

Isoniazid affects the expression of TRAK1 mRNA

NCBI chr 9:121,126,568...121,303,985
Ensembl chr 9:121,126,568...121,303,984

G

transferrin

increases expression

Isoniazid results in increased expression of TF mRNA

NCBI chr 9:103,086,075...103,107,485
Ensembl chr 9:103,081,200...103,107,643

G

tribbles pseudokinase 3

increases expression

Isoniazid results in increased expression of TRIB3 mRNA

NCBI chr 2:152,179,345...152,185,980
Ensembl chr 2:152,179,342...152,185,952

G

thioredoxin 2

affects expression

Isoniazid affects the expression of TXN2 mRNA

NCBI chr15:77,799,251...77,813,194
Ensembl chr15:77,799,247...77,813,206

G

thioredoxin reductase 1

increases expression

Isoniazid results in increased expression of TXNRD1 mRNA

NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546

G

thioredoxin reductase 2

affects expression

Isoniazid affects the expression of TXNRD2 mRNA

NCBI chr16:18,245,167...18,297,823
Ensembl chr16:18,245,134...18,297,823

G

ubiquinol-cytochrome c reductase binding protein

affects expression

Isoniazid affects the expression of UQCRB mRNA

NCBI chr13:67,048,640...67,053,414
Ensembl chr13:67,048,681...67,053,442

G

ubiquinol cytochrome c reductase core protein 2

affects expression

Isoniazid affects the expression of UQCRC2 mRNA

NCBI chr 7:120,234,412...120,258,746
Ensembl chr 7:120,234,399...120,258,747

lomefloxacin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

histocompatibility 2, M region locus 2

affects expression

lomefloxacin affects the expression of HLA-B mRNA

NCBI chr17:37,791,742...37,794,445
Ensembl chr17:37,791,742...37,794,443

G

potassium voltage-gated channel, subfamily H (eag-related), member 2

affects binding

lomefloxacin binds to KCNH2 protein

NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602

G

matrix metallopeptidase 2

increases activity
increases expression

lomefloxacin results in increased activity of MMP2 protein
lomefloxacin results in increased expression of MMP2 mRNA

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

matrix metallopeptidase 9

increases expression
increases activity

lomefloxacin results in increased expression of MMP9 mRNA
lomefloxacin results in increased activity of MMP9 protein

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

N'-acetylisoniazid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

myeloperoxidase

increases oxidation

MPO protein results in increased oxidation of (N)1-acetylisoniazid

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

pyrazine-2-carboxylic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

amino carboxymuconate semialdehyde decarboxylase

decreases activity

pyrazinoic acid metabolite results in decreased activity of ACMSD protein

NCBI chr 1:127,657,149...127,695,723
Ensembl chr 1:127,657,150...127,695,715

G

catalase

decreases expression

pyrazinoic acid results in decreased expression of CAT protein

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

glutamic pyruvic transaminase, soluble

increases activity

pyrazinoic acid results in increased activity of GPT protein

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

solute carrier family 22 (organic anion/cation transporter), member 12

multiple interactions

pyrazinoic acid promotes the reaction [SLC22A12 protein affects the transport of Uric Acid]

PMID:14747372 PMID:21074513

NCBI chr19:6,585,884...6,593,100
Ensembl chr19:6,585,875...6,593,062

G

solute carrier family 22 (organic anion transporter), member 6

multiple interactions

pyrazinoic acid inhibits the reaction [SLC22A6 protein affects the transport of Uric Acid]

NCBI chr19:8,595,360...8,605,663
Ensembl chr19:8,595,403...8,605,663

pyrazinecarboxamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family A member 1

increases expression

Pyrazinamide results in increased expression of ABCA1 mRNA

NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895

G

ATP-binding cassette, sub-family A member 3

decreases expression

Pyrazinamide results in decreased expression of ABCA3 mRNA

NCBI chr17:24,570,997...24,629,178
Ensembl chr17:24,570,924...24,629,175

G

ATP-binding cassette, sub-family B member 11

decreases expression
multiple interactions

Pyrazinamide results in decreased expression of ABCB11 mRNA; Pyrazinamide results in decreased expression of ABCB11 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein
obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCB11 mRNA]

PMID:27255380 PMID:35835356

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

ATP-binding cassette, sub-family B member 4

multiple interactions
decreases expression

obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCB4 mRNA]
Pyrazinamide results in decreased expression of ABCB4 mRNA; Pyrazinamide results in decreased expression of ABCB4 protein

NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231

G

ATP-binding cassette, sub-family B member 6

increases expression

Pyrazinamide results in increased expression of ABCB6 mRNA

NCBI chr 1:75,148,284...75,157,066
Ensembl chr 1:75,148,361...75,157,036

G

ATP-binding cassette, sub-family member 2

multiple interactions
decreases expression

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein; obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCC2 mRNA]
Pyrazinamide results in decreased expression of ABCC2 mRNA; Pyrazinamide results in decreased expression of ABCC2 protein

PMID:27255380 PMID:35835356

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

G

ATP-binding cassette, sub-family C member 3

increases expression

Pyrazinamide results in increased expression of ABCC3 mRNA; Pyrazinamide results in increased expression of ABCC3 protein

NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823

G

acetyl-Coenzyme A acyltransferase 1A

increases expression
multiple interactions

Pyrazinamide results in increased expression of ACAA1 mRNA
Fenofibrate promotes the reaction [Pyrazinamide results in increased expression of ACAA1 mRNA]; Pyrazinamide promotes the reaction [Fenofibrate results in increased expression of ACAA1 mRNA]

PMID:22431067 PMID:27071702

NCBI chr 9:119,170,113...119,179,361
Ensembl chr 9:119,168,742...119,179,365

G

acetyl-Coenzyme A acyltransferase 1B

increases expression

Pyrazinamide results in increased expression of ACAA1B mRNA

NCBI chr 9:118,977,111...118,986,149
Ensembl chr 9:118,977,091...118,986,161

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein

NCBI chr X:141,100,989...141,173,792
Ensembl chr X:141,100,989...141,173,531

G

acyl-CoA synthetase medium-chain family member 2

increases expression

Pyrazinamide results in increased expression of ACSM2 mRNA

NCBI chr 7:119,153,563...119,199,917
Ensembl chr 7:119,153,563...119,199,913

G

aldehyde dehydrogenase family 1, subfamily A1

increases expression

Pyrazinamide results in increased expression of ALDH1A1 mRNA

NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829

G

aldehyde dehydrogenase 1 family, member L1

increases expression

Pyrazinamide results in increased expression of ALDH1L1 mRNA

NCBI chr 6:90,527,751...90,576,153
Ensembl chr 6:90,463,409...90,577,185

G

alkB homolog 2, alpha-ketoglutarate-dependent dioxygenase

decreases expression

Pyrazinamide results in decreased expression of ALKBH2 mRNA

NCBI chr 5:114,261,987...114,268,782
Ensembl chr 5:114,261,987...114,266,279

G

apolipoprotein A-I

increases expression
multiple interactions

Pyrazinamide results in increased expression of APOA1 mRNA
[Fenofibrate co-treated with Pyrazinamide] results in increased expression of APOA1 mRNA

PMID:22431067 PMID:27071702

NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764

G

asparagine synthetase

increases expression

Pyrazinamide results in increased expression of ASNS mRNA

NCBI chr 6:7,675,169...7,693,209
Ensembl chr 6:7,675,169...7,693,254

G

activating transcription factor 3

increases expression

Pyrazinamide results in increased expression of ATF3 mRNA

NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236

G

activating transcription factor 4

increases expression
multiple interactions

Pyrazinamide results in increased expression of ATF4 protein
4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of ATF4 protein]
Pyrazinamide results in increased expression of ATF4 mRNA; Pyrazinamide results in increased expression of ATF4 protein

NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742

G

activating transcription factor 6

increases expression

Pyrazinamide results in increased expression of ATF6 mRNA

NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340

G

Bcl2-like 10

decreases expression

Pyrazinamide results in decreased expression of BCL2L10 mRNA

NCBI chr 9:75,255,040...75,258,922
Ensembl chr 9:75,255,040...75,258,931

G

BCL2-like 2

decreases expression

Pyrazinamide results in decreased expression of BCL2L2 mRNA

NCBI chr14:55,120,900...55,125,691
Ensembl chr14:55,120,834...55,125,691

G

B cell CLL/lymphoma 7C

increases expression

Pyrazinamide results in increased expression of BCL7C mRNA

NCBI chr 7:127,260,626...127,307,938
Ensembl chr 7:127,260,628...127,308,105

G

BCL2 modifying factor

decreases expression

Pyrazinamide results in decreased expression of BMF mRNA

NCBI chr 2:118,359,238...118,385,240
Ensembl chr 2:118,359,238...118,380,168

G

caspase 3

increases cleavage
multiple interactions

Pyrazinamide results in increased cleavage of CASP3 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3

PMID:28063906 PMID:35835356

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

catalase

decreases expression
multiple interactions

Pyrazinamide results in decreased expression of CAT protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein

PMID:28425350 PMID:36878459

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

cell division cycle and apoptosis regulator 1

decreases expression

Pyrazinamide results in decreased expression of CCAR1 mRNA

NCBI chr10:62,579,707...62,628,147
Ensembl chr10:62,579,707...62,628,065

G

cyclin E2

decreases expression

Pyrazinamide results in decreased expression of CCNE2 mRNA

NCBI chr 4:11,190,489...11,204,781
Ensembl chr 4:11,191,351...11,204,779

G

cyclin dependent kinase 20

decreases expression

Pyrazinamide results in decreased expression of CDK20 mRNA

NCBI chr13:64,580,133...64,587,536
Ensembl chr13:64,580,128...64,589,587

G

cyclin dependent kinase 4

increases expression

Pyrazinamide results in increased expression of CDK4 mRNA

NCBI chr10:126,899,404...126,903,157
Ensembl chr10:126,899,403...126,903,789

G

cyclin dependent kinase inhibitor 2D

increases expression

Pyrazinamide results in increased expression of CDKN2D mRNA

NCBI chr 9:21,199,759...21,202,553
Ensembl chr 9:21,199,706...21,202,703

G

CCAAT/enhancer binding protein beta

increases expression

Pyrazinamide results in increased expression of CEBPB mRNA

NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338

G

CCAAT/enhancer binding protein delta

increases expression

Pyrazinamide results in increased expression of CEBPD mRNA

NCBI chr16:15,705,150...15,707,409
Ensembl chr16:15,705,150...15,708,895

G

collagen, type I, alpha 1

increases expression

Pyrazinamide results in increased expression of COL1A1 mRNA

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

carnitine palmitoyltransferase 1b, muscle

multiple interactions
decreases expression

Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of CPT1B mRNA]

PMID:22431067 PMID:27071702

NCBI chr15:89,300,608...89,310,065
Ensembl chr15:89,300,608...89,310,066

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression

Pyrazinamide results in increased expression of CYP1A2 mRNA

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 2, subfamily b, polypeptide 13

increases expression

Pyrazinamide results in increased expression of CYP2B2 mRNA

NCBI chr 7:25,760,813...25,795,622
Ensembl chr 7:25,760,922...25,795,622

G

cytochrome P450, family 2, subfamily d, polypeptide 22

increases expression

Pyrazinamide results in increased expression of CYP2D4 mRNA

NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

cytochrome P450, family 3, subfamily a, polypeptide 13

decreases expression

Pyrazinamide results in decreased expression of CYP3A9 mRNA

NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881

G

cytochrome P450, family 51

increases expression

Pyrazinamide results in increased expression of CYP51 mRNA

NCBI chr 5:4,130,674...4,154,697
Ensembl chr 5:4,131,145...4,154,746

G

cytochrome P450, family 7, subfamily a, polypeptide 1

increases expression
multiple interactions

Pyrazinamide results in increased expression of CYP7A1 mRNA; Pyrazinamide results in increased expression of CYP7A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein

PMID:27255380 PMID:35835356

NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633

G

cytochrome P450, family 8, subfamily b, polypeptide 1

decreases expression
increases expression

Pyrazinamide results in decreased expression of CYP8B1 mRNA; Pyrazinamide results in decreased expression of CYP8B1 protein
Pyrazinamide results in increased expression of CYP8B1 mRNA

PMID:22431067 PMID:27255380

NCBI chr 9:121,743,422...121,745,371
Ensembl chr 9:121,743,422...121,745,371

G

DNA-damage inducible transcript 3

increases expression
multiple interactions

Pyrazinamide results in increased expression of DDIT3 protein
4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of DDIT3 protein]
Pyrazinamide results in increased expression of DDIT3 mRNA; Pyrazinamide results in increased expression of DDIT3 protein

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

dual-specificity tyrosine phosphorylation regulated kinase 2

decreases expression

Pyrazinamide results in decreased expression of DYRK2 mRNA

NCBI chr10:118,691,507...118,725,144
Ensembl chr10:118,691,508...118,706,114

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions
increases phosphorylation

4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased phosphorylation of EIF2AK3 protein]

NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229

G

eukaryotic translation initiation factor 2, subunit 1 alpha

increases phosphorylation
multiple interactions

Pyrazinamide results in increased phosphorylation of EIF2S1 protein
4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased phosphorylation of EIF2S1 protein]

NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784

G

E1A binding protein p300

decreases expression

Pyrazinamide results in decreased expression of EP300 mRNA

NCBI chr15:81,470,329...81,536,273
Ensembl chr15:81,469,552...81,536,278

G

epoxide hydrolase 1, microsomal

increases expression

Pyrazinamide results in increased expression of EPHX1 mRNA

NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469

G

excision repair cross-complementing rodent repair deficiency, complementation group 1

increases expression

Pyrazinamide results in increased expression of ERCC1 mRNA

NCBI chr 7:19,079,016...19,090,449
Ensembl chr 7:19,078,703...19,090,449

G

endoplasmic reticulum to nucleus signalling 1

increases expression

Pyrazinamide results in increased expression of ERN1 mRNA

NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678

G

fatty acid binding protein 1, liver

multiple interactions
decreases expression

Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of FABP1 mRNA]

NCBI chr 6:71,176,863...71,182,018
Ensembl chr 6:71,176,811...71,182,007

G

fatty acid binding protein 7, brain

decreases expression

Pyrazinamide results in decreased expression of FABP7 mRNA

NCBI chr10:57,661,019...57,664,546
Ensembl chr10:57,660,977...57,664,546

G

F-box and WD-40 domain protein 11

decreases expression

Pyrazinamide results in decreased expression of FBXW11 mRNA

NCBI chr11:32,592,595...32,696,816
Ensembl chr11:32,592,724...32,696,816

G

flavin containing monooxygenase 1

increases expression

Pyrazinamide results in increased expression of FMO1 mRNA

NCBI chr 1:162,657,130...162,694,170
Ensembl chr 1:162,657,130...162,694,179

G

growth arrest and DNA-damage-inducible 45 alpha

increases expression

Pyrazinamide results in increased expression of GADD45A mRNA

NCBI chr 6:67,012,080...67,014,391
Ensembl chr 6:67,012,080...67,014,441

G

growth arrest specific 2

increases expression

Pyrazinamide results in increased expression of GAS2 mRNA

NCBI chr 7:51,511,560...51,644,753
Ensembl chr 7:51,511,763...51,644,723

G

glutamic pyruvic transaminase, soluble

increases expression
increases activity
multiple interactions

Pyrazinamide results in increased expression of GPT protein
Pyrazinamide results in increased activity of GPT protein
4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of GPT protein]; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; Fenofibrate inhibits the reaction [Pyrazinamide results in increased expression of GPT protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

PMID:27071702 PMID:28063906 PMID:28425350 PMID:35835356 PMID:36878459

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

glutathione peroxidase 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]

NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273

G

glutathione S-transferase, alpha 1 (Ya)

increases expression

Pyrazinamide results in increased expression of GSTA5 mRNA

NCBI chr 9:78,137,951...78,149,965
Ensembl chr 9:78,137,938...78,149,966

G

glutathione S-transferase, alpha 4

increases expression

Pyrazinamide results in increased expression of GSTA4 mRNA

NCBI chr 9:78,099,248...78,116,631
Ensembl chr 9:78,090,056...78,116,631

G

glutathione S-transferase, mu 1

increases expression

Pyrazinamide results in increased expression of GSTM1 mRNA

NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289

G

glutathione S-transferase, mu 2

increases expression

Pyrazinamide results in increased expression of GSTM2 mRNA

NCBI chr 3:107,889,018...107,893,736
Ensembl chr 3:107,889,018...107,893,769

G

glutathione S-transferase, pi 1

increases expression

Pyrazinamide results in increased expression of GSTP1 mRNA

NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985

G

glutathione S-transferase, theta 1

multiple interactions

GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide]

NCBI chr10:75,619,647...75,634,418
Ensembl chr10:75,619,647...75,634,418

G

hypoxia inducible factor 1, alpha subunit

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304

G

3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1

increases expression

Pyrazinamide results in increased expression of HMGCS1 mRNA

NCBI chr13:120,151,887...120,169,796
Ensembl chr13:120,151,915...120,169,796

G

3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2

increases expression

Pyrazinamide results in increased expression of HMGCS2 mRNA

NCBI chr 3:98,187,747...98,218,054
Ensembl chr 3:98,187,751...98,218,054

G

heme oxygenase 1

increases expression

Pyrazinamide results in increased expression of HMOX1 mRNA

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

hydroxysteroid 11-beta dehydrogenase 1

increases expression

Pyrazinamide results in increased expression of HSD11B1 mRNA

NCBI chr 1:192,903,917...192,946,345
Ensembl chr 1:192,903,942...192,946,383

G

heat shock protein 5

multiple interactions
increases expression

4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of HSPA5 protein]
Pyrazinamide results in increased expression of HSPA5 mRNA; Pyrazinamide results in increased expression of HSPA5 protein

NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559

G

inositol 1,4,5-trisphosphate receptor 1

decreases expression

Pyrazinamide results in decreased expression of ITPR1 mRNA

NCBI chr 6:108,190,044...108,528,077
Ensembl chr 6:108,190,057...108,528,070

G

lipoprotein lipase

multiple interactions
decreases expression

Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of LPL mRNA]

NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100

G

malic enzyme 1, NADP(+)-dependent, cytosolic

increases expression

Pyrazinamide results in increased expression of ME1 mRNA

PMID:22431067 PMID:27071702

NCBI chr 9:86,463,416...86,577,967
Ensembl chr 9:86,463,424...86,578,006

G

microsomal glutathione S-transferase 3

increases expression

Pyrazinamide results in increased expression of MGST3 mRNA

NCBI chr 1:167,199,535...167,221,410
Ensembl chr 1:167,199,535...167,221,410

G

Mix paired-like homeobox

decreases expression

Pyrazinamide results in decreased expression of MIXL1 mRNA

NCBI chr 1:180,520,608...180,524,599
Ensembl chr 1:180,520,608...180,524,599

G

mitochondrial ribosomal protein S14

decreases expression

Pyrazinamide results in decreased expression of MRPS14 mRNA

NCBI chr 1:160,022,785...160,028,756
Ensembl chr 1:160,022,785...160,029,740

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions
decreases expression

obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of NR0B2 mRNA]

NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions
decreases expression

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4; obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of NR1H4 mRNA]
Pyrazinamide results in decreased expression of NR1H4 mRNA; Pyrazinamide results in decreased expression of NR1H4 protein

PMID:27255380 PMID:35835356

NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447

G

NAD(P) dependent steroid dehydrogenase-like

increases expression

Pyrazinamide results in increased expression of NSDHL mRNA

NCBI chr X:71,962,127...72,002,134
Ensembl chr X:71,962,163...72,002,120

G

neurotrophic tyrosine kinase, receptor, type 1

decreases expression

Pyrazinamide results in decreased expression of NTRK1 mRNA

NCBI chr 3:87,685,551...87,702,549
Ensembl chr 3:87,685,551...87,702,469

G

PERP, TP53 apoptosis effector

increases expression

Pyrazinamide results in increased expression of PERP mRNA

NCBI chr10:18,720,819...18,732,821
Ensembl chr10:18,720,768...18,732,821

G

3-phosphoglycerate dehydrogenase

increases expression

Pyrazinamide results in increased expression of PHGDH mRNA

NCBI chr 3:98,220,487...98,247,285
Ensembl chr 3:98,220,486...98,247,306

G

peroxisome proliferator activated receptor alpha

multiple interactions
decreases expression

[Pyrazinamide co-treated with Glucose] binds to PPARA protein; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]
Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of PPARA mRNA]
Pyrazinamide results in decreased expression of PPARA mRNA; Pyrazinamide results in decreased expression of PPARA protein

PMID:18812576 PMID:27071702

NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020

G

protein phosphatase 2, regulatory subunit A, alpha

increases expression

Pyrazinamide results in increased expression of PPP2R1A mRNA

NCBI chr17:21,165,716...21,186,167
Ensembl chr17:21,165,573...21,186,178

G

prominin 1

decreases expression

Pyrazinamide results in decreased expression of PROM1 mRNA

NCBI chr 5:44,150,963...44,260,850
Ensembl chr 5:44,150,962...44,259,374

G

solute carrier family 10 (sodium/bile acid cotransporter family), member 1

increases expression
multiple interactions

Pyrazinamide results in increased expression of SLC10A1 mRNA; Pyrazinamide results in increased expression of SLC10A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1

PMID:27255380 PMID:35835356

NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479

G

solute carrier family 16 (monocarboxylic acid transporters), member 11

decreases expression

Pyrazinamide results in decreased expression of SLC16A11 mRNA

NCBI chr11:70,104,717...70,107,239
Ensembl chr11:70,103,578...70,107,243

G

solute carrier family 17 (sodium phosphate), member 1

increases expression

Pyrazinamide results in increased expression of SLC17A1 mRNA

NCBI chr13:24,051,607...24,079,713
Ensembl chr13:24,051,733...24,079,713

G

solute carrier family 22 (organic anion/cation transporter), member 12

affects activity

Pyrazinamide affects the activity of SLC22A12 protein

NCBI chr19:6,585,884...6,593,100
Ensembl chr19:6,585,875...6,593,062

G

solute carrier family 22 (organic cation transporter), member 13

decreases expression

Pyrazinamide results in decreased expression of SLC22A13 mRNA

NCBI chr 9:119,020,618...119,038,171
Ensembl chr 9:119,022,040...119,038,164

G

solute carrier family 25, member 39

increases expression

Pyrazinamide results in increased expression of SLC25A39 mRNA

NCBI chr11:102,293,795...102,299,501
Ensembl chr11:102,293,811...102,298,772

G

solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 4

decreases expression

Pyrazinamide results in decreased expression of SLC25A4 mRNA

NCBI chr 8:46,660,205...46,664,099
Ensembl chr 8:46,659,834...46,664,321

G

solute carrier family 25, member 42

decreases expression

Pyrazinamide results in decreased expression of SLC25A42 mRNA

NCBI chr 8:70,636,990...70,664,931
Ensembl chr 8:70,636,990...70,664,955

G

solute carrier family 29 (nucleoside transporters), member 1

decreases expression

Pyrazinamide results in decreased expression of SLC29A1 mRNA

NCBI chr17:45,896,126...45,910,544
Ensembl chr17:45,896,126...45,910,532

G

solute carrier family 51, alpha subunit

decreases expression

Pyrazinamide results in decreased expression of SLC51A mRNA; Pyrazinamide results in decreased expression of SLC51A protein

NCBI chr16:32,294,396...32,306,697
Ensembl chr16:32,293,322...32,306,697

G

solute carrier family 51, beta subunit

multiple interactions
decreases expression

obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of SLC51B mRNA]
Pyrazinamide results in decreased expression of SLC51B mRNA; Pyrazinamide results in decreased expression of SLC51B protein

NCBI chr 9:65,320,035...65,330,055
Ensembl chr 9:65,319,996...65,330,237

G

solute carrier family 6 (neurotransmitter transporter, glycine), member 9

decreases expression

Pyrazinamide results in decreased expression of SLC6A9 mRNA

NCBI chr 4:117,692,240...117,726,502
Ensembl chr 4:117,691,703...117,732,395

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 10

decreases expression

Pyrazinamide results in decreased expression of SLC7A10 mRNA

NCBI chr 7:34,885,520...34,900,539
Ensembl chr 7:34,885,810...34,900,539

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 11

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]

NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063

G

solute carrier organic anion transporter family, member 1a4

increases expression

Pyrazinamide results in increased expression of SLCO1A4 mRNA; Pyrazinamide results in increased expression of SLCO1A4 protein

NCBI chr 6:141,751,164...141,802,011
Ensembl chr 6:141,751,166...141,801,925

G

solute carrier organic anion transporter family, member 1b2

decreases expression
multiple interactions

Pyrazinamide results in decreased expression of SLCO1B2 mRNA; Pyrazinamide results in decreased expression of SLCO1B2 protein
obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of SLCO1B2 mRNA]

NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372

G

solute carrier organic anion transporter family, member 4a1

decreases expression

Pyrazinamide results in decreased expression of SLCO4A1 mRNA

NCBI chr 2:180,098,019...180,116,646
Ensembl chr 2:180,098,038...180,116,660

G

spermidine synthase

increases expression

Pyrazinamide results in increased expression of SRM mRNA

NCBI chr 4:148,675,970...148,679,076
Ensembl chr 4:148,675,960...148,679,450

G

sulfotransferase family, cytosolic, 1C, member 2

decreases expression

Pyrazinamide results in decreased expression of SULT1C2A mRNA

NCBI chr17:54,136,665...54,152,986
Ensembl chr17:54,136,665...54,153,367

G

sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1

decreases expression

Pyrazinamide results in decreased expression of SULT2A1 mRNA

NCBI chr 7:13,530,171...13,571,335
Ensembl chr 7:13,530,171...13,571,334

G

TOPBP1-interacting checkpoint and replication regulator

decreases expression

Pyrazinamide results in decreased expression of TICRR mRNA

NCBI chr 7:79,309,944...79,347,896
Ensembl chr 7:79,309,944...79,347,896

G

transmembrane protein 176A

increases expression

Pyrazinamide results in increased expression of TMEM176A mRNA

NCBI chr 6:48,818,417...48,822,298
Ensembl chr 6:48,817,853...48,824,005

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases expression

Pyrazinamide results in increased expression of UGT1A2 mRNA

NCBI chr 1:88,128,333...88,147,724
Ensembl chr 1:88,128,323...88,146,719

G

voltage-dependent anion channel 1

increases expression

Pyrazinamide results in increased expression of VDAC1 mRNA

NCBI chr11:52,251,905...52,280,224
Ensembl chr11:52,251,687...52,280,224

G

X-box binding protein 1

increases expression

Pyrazinamide results in increased expression of XBP1 mRNA alternative form

NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide

increases expression

Pyrazinamide results in increased expression of YWHAH mRNA

NCBI chr 5:33,176,160...33,185,310
Ensembl chr 5:33,176,160...33,185,310

rifabutin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arylacetamide deacetylase

multiple interactions
decreases acetylation

AADAC mRNA affects the reaction [Rifabutin results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]

NCBI chr 3:59,939,209...59,947,578
Ensembl chr 3:59,933,138...59,947,581

G

ATP-binding cassette, sub-family B member 11

decreases activity

Rifabutin results in decreased activity of ABCB11 protein

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

ATP-binding cassette, sub-family B member 1A

increases expression

Rifabutin results in increased expression of ABCB1 mRNA

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

nuclear receptor subfamily 1, group I, member 2

increases activity

Rifabutin results in increased activity of NR1I2 protein

NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186

rifampicin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

RIKEN cDNA 1700011L22 gene

decreases expression

Rifampin results in decreased expression of C4ORF51 mRNA

NCBI chr 8:79,937,059...79,975,212
Ensembl chr 8:79,937,060...79,975,199

G

RIKEN cDNA 4921517D22 gene

decreases expression

Rifampin results in decreased expression of C9ORF153 mRNA

NCBI chr13:59,835,216...59,841,917
Ensembl chr13:59,835,216...59,841,922

G

arylacetamide deacetylase

multiple interactions
increases hydrolysis
decreases acetylation

AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]
AADAC protein results in increased hydrolysis of Rifampin

PMID:21856291 PMID:22207054

NCBI chr 3:59,939,209...59,947,578
Ensembl chr 3:59,933,138...59,947,581

G

ATP-binding cassette, sub-family A member 1

decreases expression
increases expression

Rifampin results in decreased expression of ABCA1 mRNA; Rifampin results in decreased expression of ABCA1 protein
Rifampin results in increased expression of ABCA1 mRNA; Rifampin results in increased expression of ABCA1 protein

PMID:15883047 PMID:17088262

NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895

G

ATP-binding cassette, sub-family A member 2

increases expression

Rifampin results in increased expression of ABCA2 mRNA

NCBI chr 2:25,318,611...25,338,556
Ensembl chr 2:25,318,715...25,338,552

G

ATP-binding cassette, sub-family A member 8b

decreases expression

Rifampin results in decreased expression of ABCA8 mRNA

NCBI chr11:109,823,016...109,886,642
Ensembl chr11:109,823,016...109,886,671

G

ATP-binding cassette, sub-family B member 11

decreases expression
multiple interactions
decreases activity

Rifampin results in decreased expression of ABCB11 mRNA
Rifampin results in decreased expression of ABCB11 protein
[Rifampin co-treated with Isoniazid] results in decreased expression of ABCB11 protein
tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 protein]
Rifampin results in decreased activity of ABCB11 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein; Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Rifampin results in decreased expression of ABCB11 mRNA; Rifampin results in decreased expression of ABCB11 protein

PMID:12135489 PMID:16837569 PMID:20829430 PMID:24014644 PMID:25886055 More...

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

ATP-binding cassette, sub-family B member 1A

affects activity
increases expression
multiple interactions
decreases activity

Rifampin affects the activity of ABCB1 protein
Rifampin results in increased expression of ABCB1 mRNA; Rifampin results in increased expression of ABCB1 protein
[Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate
[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; Rifampin promotes the reaction [ABCB1 protein results in increased transport of Digoxin]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter]

PMID:8632764 PMID:11744607 PMID:14722322 PMID:15276086 PMID:15290871 More...

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

ATP-binding cassette, sub-family B member 4

increases expression

Rifampin results in increased expression of ABCB4 mRNA

NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231

G

ATP-binding cassette, sub-family B member 6

increases expression

Rifampin results in increased expression of ABCB6 mRNA

NCBI chr 1:75,148,284...75,157,066
Ensembl chr 1:75,148,361...75,157,036

G

ATP-binding cassette, sub-family C member 1

increases expression

Rifampin results in increased expression of ABCC1 mRNA

PMID:17191263 PMID:35972551

NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601

G

ATP-binding cassette, sub-family C member 10

increases expression

Rifampin results in increased expression of ABCC10 mRNA

NCBI chr17:46,614,146...46,638,954
Ensembl chr17:46,614,147...46,639,278

G

ATP-binding cassette, sub-family member 2

affects export
multiple interactions
increases expression

ABCC2 protein affects the export of Rifampin
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein
Rifampin results in increased expression of ABCC2; Rifampin results in increased expression of ABCC2 mRNA; Rifampin results in increased expression of ABCC2 protein
[Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein

PMID:11836020 PMID:12206135 PMID:15652233 PMID:16837569 PMID:16952291 More...

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

G

ATP-binding cassette, sub-family C member 3

multiple interactions
increases expression
increases activity

[Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; Rifampin inhibits the reaction [decitabine results in increased expression of ABCC3 mRNA]
Rifampin results in increased expression of ABCC3 mRNA
Rifampin results in increased activity of ABCC3 protein

PMID:14570758 PMID:16837569 PMID:16952291 PMID:19041851 PMID:20832446 More...

NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823

G

ATP-binding cassette, sub-family C member 5

increases expression

Rifampin results in increased expression of ABCC5 mRNA

NCBI chr16:20,150,053...20,245,178
Ensembl chr16:20,150,053...20,245,144

G

ATP-binding cassette, sub-family C member 6

increases expression

Rifampin results in increased expression of ABCC6 mRNA

NCBI chr 7:45,625,804...45,679,915
Ensembl chr 7:45,616,979...45,679,726

G

ATP-binding cassette, sub-family F member 1

increases expression

Rifampin results in increased expression of ABCF1 mRNA

NCBI chr17:36,267,711...36,280,642
Ensembl chr17:36,267,711...36,280,653

G

ATP binding cassette subfamily G member 1

increases expression

Rifampin results in increased expression of ABCG1 mRNA; Rifampin results in increased expression of ABCG1 protein

PMID:12040753 PMID:17088262

NCBI chr17:31,276,668...31,336,958
Ensembl chr17:31,276,649...31,336,962

G

ATP binding cassette subfamily G member 2 (Junior blood group)

increases expression
multiple interactions

Rifampin results in increased expression of ABCG2 mRNA; Rifampin results in increased expression of ABCG2 protein
Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA]; Rifampin promotes the reaction [Lipopolysaccharides results in decreased expression of ABCG2 mRNA]

PMID:16837569 PMID:27199754 PMID:35972551 PMID:38423481

NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661

G

ATP binding cassette subfamily G member 8

increases expression

Rifampin results in increased expression of ABCG8 mRNA

NCBI chr17:84,983,730...85,007,761
Ensembl chr17:84,983,730...85,007,761

G

ABI family member 3

decreases expression

Rifampin results in decreased expression of ABI3 mRNA

NCBI chr11:95,720,898...95,733,302
Ensembl chr11:95,720,900...95,733,302

G

acetyl-Coenzyme A carboxylase alpha

increases expression

Rifampin results in increased expression of ACACA mRNA

NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477

G

angiotensin converting enzyme 2

decreases expression

Rifampin results in decreased expression of ACE2 mRNA

NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein

NCBI chr X:141,100,989...141,173,792
Ensembl chr X:141,100,989...141,173,531

G

ARP10 actin-related protein 10

increases expression

Rifampin results in increased expression of ACTR10 mRNA

NCBI chr12:70,984,631...71,011,492
Ensembl chr12:70,984,631...71,011,492

G

alcohol dehydrogenase 1 (class I)

increases expression

Rifampin results in increased expression of ADH1C mRNA

NCBI chr 3:137,983,346...137,996,459
Ensembl chr 3:137,966,752...137,996,459

G

adiponectin, C1Q and collagen domain containing

multiple interactions

[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of ADIPOQ mRNA

NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778

G

adenosine A2a receptor

decreases expression

Rifampin results in decreased expression of ADORA2A mRNA

NCBI chr10:75,152,711...75,170,626
Ensembl chr10:75,152,711...75,170,618

G

ArfGAP with GTPase domain, ankyrin repeat and PH domain 2

decreases expression

Rifampin results in decreased expression of AGAP2 mRNA

NCBI chr10:126,911,154...126,929,039
Ensembl chr10:126,911,153...126,929,038

G

aryl-hydrocarbon receptor

multiple interactions
increases expression

[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in decreased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of AHR protein; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA]
Rifampin results in increased expression of AHR mRNA; Rifampin results in increased expression of AHR protein

PMID:22733800 PMID:28428138

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

aldo-keto reductase family 1, member B10

multiple interactions
increases expression

pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]

NCBI chr 6:34,361,182...34,373,884
Ensembl chr 6:34,361,153...34,373,885

G

aminolevulinic acid synthase 1

increases expression

Rifampin results in increased expression of ALAS1 mRNA

PMID:24259679 PMID:24552687

NCBI chr 9:106,110,654...106,125,153
Ensembl chr 9:106,110,654...106,125,853

G

alkaline phosphatase, liver/bone/kidney

multiple interactions
increases activity

[Rifampin co-treated with Isoniazid] results in increased activity of ALPL protein
Rifampin results in increased activity of ALPL protein

NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695

G

angiopoietin-like 3

decreases expression

Rifampin results in decreased expression of ANGPTL3 mRNA

NCBI chr 4:98,919,191...98,926,429
Ensembl chr 4:98,919,191...98,934,348

G

angiopoietin-like 4

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of ANGPTL4 mRNA

NCBI chr17:33,993,874...34,000,549
Ensembl chr17:33,992,724...34,000,804

G

ankyrin repeat domain 40

increases expression

Rifampin results in increased expression of TMPRSS2 mRNA

NCBI chr11:94,218,827...94,232,673
Ensembl chr11:94,218,827...94,232,667

G

ankyrin repeat domain 65

decreases expression

Rifampin results in decreased expression of ANKRD65 mRNA

NCBI chr 4:155,875,432...155,884,132
Ensembl chr 4:155,874,896...155,877,659

G

ankyrin repeat and sterile alpha motif domain containing 1B

decreases expression

Rifampin results in decreased expression of ANKS1B mRNA

NCBI chr10:89,707,238...90,809,162
Ensembl chr10:89,709,371...90,809,162

G

annexin A5

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA

NCBI chr 3:36,503,072...36,530,036
Ensembl chr 3:36,503,072...36,530,043

G

apolipoprotein B

decreases expression
multiple interactions
affects secretion

Rifampin results in decreased expression of APOB mRNA
ursodoxicoltaurine inhibits the reaction [Rifampin results in decreased expression of APOB mRNA]
Rifampin affects the secretion of APOB protein

NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835

G

apolipoprotein C-III

decreases secretion
decreases expression

Rifampin results in decreased secretion of APOC3 protein
Rifampin results in decreased expression of APOC3 mRNA

NCBI chr 9:46,144,348...46,146,934
Ensembl chr 9:46,144,231...46,146,934

G

aquaporin 3

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of AQP3 mRNA

NCBI chr 4:41,092,724...41,098,183
Ensembl chr 4:41,092,722...41,098,183

G

aquaporin 4

decreases expression

Rifampin results in decreased expression of AQP4 mRNA

NCBI chr18:15,522,451...15,544,039
Ensembl chr18:15,522,553...15,544,039

G

arylsulfatase J

decreases expression

Rifampin results in decreased expression of ARSJ mRNA

NCBI chr 3:126,157,566...126,234,025
Ensembl chr 3:126,157,333...126,234,024

G

activating transcription factor 3

multiple interactions

[Rifampin co-treated with Cobicistat] results in increased expression of ATF3 mRNA

NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236

G

activating transcription factor 4

multiple interactions
increases expression

ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein]
Rifampin results in increased expression of ATF4 mRNA; Rifampin results in increased expression of ATF4 protein
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 protein]

PMID:24638036 PMID:27470132

NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742

G

activating transcription factor 6

increases expression

Rifampin results in increased expression of ATF6 mRNA

NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340

G

ataxia telangiectasia mutated

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein
Rifampin results in decreased expression of ATM mRNA

PMID:21224054 PMID:24552687

NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040

G

ATPase, H+ transporting, lysosomal V0 subunit A1

increases expression
multiple interactions

Rifampin results in increased expression of ATP6V0A1 protein
[Rotenone co-treated with Rifampin] results in increased expression of ATP6V0A1 protein; Rifampin inhibits the reaction [Rotenone results in decreased expression of ATP6V0A1 mRNA]; Rotenone inhibits the reaction [Rifampin results in increased expression of ATP6V0A1 protein]

NCBI chr11:100,899,262...100,954,545
Ensembl chr11:100,900,278...100,954,545

G

ATPase, H+ transporting, lysosomal V0 subunit D1

multiple interactions

ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]]

NCBI chr 8:106,251,093...106,292,696
Ensembl chr 8:106,251,097...106,292,679

G

ATRX, chromatin remodeler

increases expression

Rifampin results in increased expression of ATRX mRNA

NCBI chr X:104,841,221...104,972,978
Ensembl chr X:104,841,221...104,973,009

G

BCL2-associated X protein

multiple interactions
decreases expression

[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of BAX mRNA; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein]
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein
Rifampin results in decreased expression of BAX protein

PMID:11958592 PMID:12645856 PMID:21224054 PMID:21419764 PMID:31629065 More...

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

increases expression
multiple interactions

Rifampin results in increased expression of BCL2 protein
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein
[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein]

PMID:11958592 PMID:21419764 PMID:31629065

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

BCL2-like 1

increases expression
multiple interactions

Rifampin results in increased expression of BCL2L1 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA

PMID:11958592 PMID:12645856 PMID:21224054

NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648

G

basic helix-loop-helix family, member e40

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of BHLHE40 mRNA

NCBI chr 6:108,637,590...108,643,886
Ensembl chr 6:108,637,590...108,643,886

G

bone morphogenetic protein 4

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of BMP4 mRNA

NCBI chr14:46,620,982...46,628,126
Ensembl chr14:46,620,977...46,628,126

G

carbonic anhydrase 1

decreases expression

Rifampin results in decreased expression of CA1 mRNA

NCBI chr 3:14,831,274...14,873,425
Ensembl chr 3:14,831,276...14,873,428

G

caspase 1

multiple interactions

Rifampin inhibits the reaction [Rotenone results in increased cleavage of CASP1 protein]

NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290

G

caspase 3

multiple interactions

Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3
[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]

PMID:11958592 PMID:12645856 PMID:17936189 PMID:21419764 PMID:23764483 More...

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

multiple interactions

Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]

PMID:11958592 PMID:12645856

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

catalase

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

carbonyl reductase 3

multiple interactions

[Rifampin co-treated with Cobicistat] results in increased expression of CBR3 mRNA

NCBI chr16:93,480,107...93,487,879
Ensembl chr16:93,480,103...93,487,878

G

C-C motif chemokine ligand 2

decreases expression

Rifampin results in decreased expression of CCL2 mRNA

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 5

decreases expression

Rifampin results in decreased expression of CCL5 protein

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

G

cellular communication network factor 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CCN1 mRNA

NCBI chr 3:145,352,726...145,355,740
Ensembl chr 3:145,352,731...145,355,736

G

cyclin D1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

cyclin G1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA

NCBI chr11:40,639,379...40,646,044
Ensembl chr11:40,639,379...40,646,138

G

C-C motif chemokine receptor 6

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CCR6 mRNA

NCBI chr17:8,454,875...8,477,353
Ensembl chr17:8,454,875...8,475,973

G

C-C motif chemokine receptor 7

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CCR7 mRNA

NCBI chr11:99,035,025...99,045,903
Ensembl chr11:99,035,022...99,045,903

G

CD36 molecule

increases expression

Rifampin results in increased expression of CD36 mRNA

NCBI chr 5:17,986,680...18,093,828
Ensembl chr 5:17,986,688...18,093,799

G

cyclin dependent kinase inhibitor 1A

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

cyclin dependent kinase inhibitor 2B

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA

NCBI chr 4:89,224,526...89,229,269
Ensembl chr 4:89,224,536...89,229,276

G

CCAAT/enhancer binding protein alpha

multiple interactions

[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPA mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]

NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353

G

CCAAT/enhancer binding protein beta

multiple interactions

[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPB mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]

NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338

G

CCAAT/enhancer binding protein delta

multiple interactions

[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPD mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]

NCBI chr16:15,705,150...15,707,409
Ensembl chr16:15,705,150...15,708,895

G

carboxylesterase 1D

increases expression

Rifampin results in increased expression of CES1 protein

NCBI chr 8:93,892,700...93,924,432
Ensembl chr 8:93,892,696...93,924,466

G

carboxylesterase 2A

multiple interactions

[Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CES2A mRNA

NCBI chr 8:105,460,635...105,468,266
Ensembl chr 8:105,460,635...105,468,266

G

carboxylesterase 2H

increases expression
multiple interactions

Rifampin results in increased expression of CES2 mRNA; Rifampin results in increased expression of CES2 protein
Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA]

PMID:10640517 PMID:17003103

NCBI chr 8:105,727,462...105,747,042
Ensembl chr 8:105,727,485...105,747,810

G

CASP8 and FADD-like apoptosis regulator

multiple interactions
increases expression

Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]
Rifampin results in increased expression of CFLAR protein

PMID:11958592 PMID:12645856

NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043

G

checkpoint kinase 2

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA

NCBI chr 5:110,987,668...111,022,006
Ensembl chr 5:110,987,845...111,022,011

G

CDKN1A interacting zinc finger protein 1

decreases expression

Rifampin results in decreased expression of CIZ1 mRNA

NCBI chr 2:32,252,724...32,268,311
Ensembl chr 2:32,242,339...32,270,982

G

CDC-like kinase 2

decreases expression

Rifampin results in decreased expression of CLK2 mRNA

NCBI chr 3:89,072,102...89,084,394
Ensembl chr 3:89,072,102...89,084,228

G

centlein, centrosomal protein

increases expression

Rifampin results in increased expression of CNTLN mRNA

NCBI chr 4:84,800,024...85,050,160
Ensembl chr 4:84,802,546...85,050,158

G

carnitine palmitoyltransferase 1a, liver

increases expression

Rifampin results in increased expression of CPT1A mRNA

NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733

G

corticotropin releasing hormone receptor 1

decreases expression

Rifampin results in decreased expression of CRHR1 mRNA

NCBI chr11:104,021,289...104,066,349
Ensembl chr11:104,023,681...104,066,349

G

C-reactive protein, pentraxin-related

multiple interactions

[Floxacillin co-treated with Gentamicins co-treated with Rifampin] results in increased expression of CRP protein

NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598

G

casein kinase 1, gamma 1

decreases expression

Rifampin results in decreased expression of CSNK1G1 mRNA

NCBI chr 9:65,816,235...65,952,297
Ensembl chr 9:65,816,206...65,952,297

G

C-X-C motif chemokine ligand 1

increases expression

Rifampin results in increased expression of CXCL1 protein

NCBI chr 5:91,039,104...91,040,980
Ensembl chr 5:91,039,100...91,040,974

G

C-X-C motif chemokine ligand 10

multiple interactions
affects expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA
Rifampin affects the expression of CXCL10 protein

PMID:21224054 PMID:25051504

NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748

G

cytochrome b5 reductase-like

increases expression

Rifampin results in increased expression of CYB5RL mRNA

NCBI chr 4:106,924,035...106,945,204
Ensembl chr 4:106,924,185...106,945,465

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases activity
increases expression

Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
Rifampin results in increased activity of CYP1A1 protein
Rifampin results in increased expression of CYP1A1 mRNA; Rifampin results in increased expression of CYP1A1 protein
[Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP1A1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 protein; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A1 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]

PMID:12040753 PMID:18493746 PMID:19118567 PMID:19409404 PMID:22733800 More...

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
increases expression

[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A2 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]
Rifampin results in increased expression of CYP1A2 mRNA
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA]; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein]
Rifampin results in increased expression of CYP1A2 mRNA; Rifampin results in increased expression of CYP1A2 protein

PMID:15977188 PMID:17590308 PMID:18493746 PMID:25835148 PMID:29162470 More...

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1B1 mRNA

PMID:21224054 PMID:29162470

NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490

G

cytochrome P450, family 24, subfamily a, polypeptide 1

multiple interactions
increases expression
increases activity

NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter]
Rifampin results in increased activity of CYP24A1 protein

PMID:15630458 PMID:21127053

NCBI chr 2:170,324,877...170,339,065
Ensembl chr 2:170,324,628...170,339,065

G

cytochrome P450, family 26, subfamily a, polypeptide 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP26A1 mRNA

NCBI chr19:37,686,186...37,689,984
Ensembl chr19:37,686,246...37,689,984

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions
increases expression

Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]
Rifampin results in increased expression of CYP27A1 mRNA

NCBI chr 1:74,752,311...74,777,056
Ensembl chr 1:74,752,733...74,777,051

G

cytochrome P450, family 2, subfamily a, polypeptide 22

increases expression

Rifampin results in increased expression of CYP2A1 mRNA

NCBI chr 7:26,631,564...26,638,838
Ensembl chr 7:26,631,056...26,638,809

G

cytochrome P450, family 2, subfamily a, polypeptide 4

increases expression

Rifampin results in increased expression of CYP2A4 mRNA

NCBI chr 7:26,006,617...26,014,513
Ensembl chr 7:26,006,594...26,014,513

G

cytochrome P450, family 2, subfamily a, polypeptide 5

multiple interactions
increases expression
increases activity

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2A5 mRNA
Rifampin results in increased expression of CYP2A6 mRNA; Rifampin results in increased expression of CYP2A6 protein
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP2A6 mRNA; Rifampin promotes the reaction [NR1I2 protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [PPARGC1A protein binds to CYP2A6 promoter]
Rifampin results in increased expression of CYP2A5 mRNA
Rifampin results in increased activity of CYP2A5 protein

PMID:11038160 PMID:14709624 PMID:15629111 PMID:16857725 PMID:19118567 More...

NCBI chr 7:26,534,764...26,542,689
Ensembl chr 7:26,534,730...26,542,973

G

cytochrome P450, family 2, subfamily b, polypeptide 10

multiple interactions
increases expression
increases activity

[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA
Rifampin results in increased expression of CYP2B10 mRNA
Rifampin results in increased expression of CYP2B6 mRNA; Rifampin results in increased expression of CYP2B6 protein
[Rifampin co-treated with Monocrotophos] results in increased activity of CYP2B6 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Dexamethasone promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP2B6 protein
Rifampin results in increased activity of CYP2B6 protein

PMID:12040753 PMID:12571232 PMID:12695351 PMID:14709624 PMID:14977870 More...

NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049

G

cytochrome P450, family 2, subfamily b, polypeptide 9

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2B9 mRNA
Rifampin results in decreased expression of CYP2B9 mRNA

PMID:21224054 PMID:30503582

NCBI chr 7:25,872,775...25,910,086
Ensembl chr 7:25,872,836...25,910,086

G

cytochrome P450, family 2, subfamily c, polypeptide 29

multiple interactions
increases expression
affects binding
increases activity

[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein
Rifampin results in increased expression of CYP2C29 mRNA
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]
Rifampin results in increased expression of CYP2C8 mRNA; Rifampin results in increased expression of CYP2C8 protein
[Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter
Rifampin results in increased activity of CYP2C8 protein

PMID:12040753 PMID:15771232 PMID:15933212 PMID:17954527 PMID:19118567 More...

NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157

G

cytochrome P450, family 2. subfamily c, polypeptide 37

increases expression

Rifampin results in increased expression of CYP2C37 mRNA

NCBI chr19:39,980,868...40,000,687
Ensembl chr19:39,980,868...40,000,687

G

cytochrome P450, family 2, subfamily c, polypeptide 38

multiple interactions
increases activity
increases expression

Rifampin results in increased expression of and results in increased activity of CYP2C19 protein
Rifampin results in increased activity of CYP2C19 protein
Rifampin results in increased expression of CYP2C19 mRNA; Rifampin results in increased expression of CYP2C19 protein

PMID:12584154 PMID:14709624 PMID:15629111 PMID:17954527 PMID:19118567 More...

NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519

G

cytochrome P450, family 2, subfamily c, polypeptide 52, pseudogene

decreases expression

Rifampin results in decreased expression of CYP2C18 mRNA; Rifampin results in decreased expression of CYP2C18 protein

PMID:22258563 PMID:31629065

NCBI chr19:38,965,106...38,992,071
Ensembl chr19:38,965,091...38,991,733

G

cytochrome P450, family 2, subfamily c, polypeptide 65

multiple interactions
affects response to substance
increases expression
increases activity

Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP2C9 mRNA]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP2C9 mRNA]; Rifampin results in increased activity of and results in increased expression of CYP2C9 protein; Rifampin results in increased expression of and results in increased activity of CYP2C9 protein
CYP2C9 alternative form affects the susceptibility to Rifampin
Rifampin results in increased expression of CYP2C9 mRNA; Rifampin results in increased expression of CYP2C9 protein
Rifampin results in increased activity of CYP2C9 protein

PMID:14600250 PMID:14709624 PMID:14722322 PMID:15629111 PMID:15802389 More...

NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388

G

cytochrome P450, family 2, subfamily d, polypeptide 22

increases expression
increases activity
decreases expression

Rifampin results in increased expression of CYP2D6 mRNA
Rifampin results in increased activity of CYP2D6 protein
Rifampin results in decreased expression of CYP2D22 mRNA

PMID:19041851 PMID:30503582 PMID:33844597

NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461

G

cytochrome P450, family 2, subfamily d, polypeptide 9

decreases expression

Rifampin results in decreased expression of CYP2D9 mRNA

NCBI chr15:82,336,578...82,341,028
Ensembl chr15:82,317,638...82,341,046

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases activity
decreases expression
multiple interactions
increases expression

Rifampin results in increased activity of CYP2E1 protein
Rifampin results in decreased expression of CYP2E1 mRNA
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with dendrobine] results in decreased expression of CYP2E1 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP2E1 mRNA
Rifampin results in increased expression of CYP2E1 mRNA; Rifampin results in increased expression of CYP2E1 protein
[Rifampin co-treated with Monocrotophos] results in increased activity of CYP2E1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 protein
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]

PMID:15132840 PMID:18071298 PMID:22258563 PMID:22733800 PMID:25835148 More...

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

cytochrome P450, family 2, subfamily f, polypeptide 2

decreases expression

Rifampin results in decreased expression of CYP2F1 mRNA

NCBI chr 7:26,819,380...26,833,085
Ensembl chr 7:26,819,334...26,833,085

G

cytochrome P450, family 2, subfamily j, polypeptide 9

decreases expression

Rifampin results in decreased expression of CYP2J2 mRNA

NCBI chr 4:96,456,661...96,480,748
Ensembl chr 4:96,456,666...96,479,815

G

cytochrome P450, family 2, subfamily s, polypeptide 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA

NCBI chr 7:25,501,894...25,515,950
Ensembl chr 7:25,501,900...25,516,338

G

cytochrome P450, family 3, subfamily a, polypeptide 11

multiple interactions
increases expression

[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A11 mRNA; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CYP3A11 mRNA; sulforaphane inhibits the reaction [Rifampin results in increased expression of CYP3A11 mRNA]
Rifampin results in increased expression of CYP3A11 mRNA; Rifampin results in increased expression of CYP3A11 protein

PMID:20869979 PMID:21224054 PMID:22467028 PMID:23153560 PMID:25835148 More...

NCBI chr 5:145,791,417...145,816,664
Ensembl chr 5:145,791,236...145,816,774

G

cytochrome P450, family 3, subfamily a, polypeptide 13

increases expression

Rifampin results in increased expression of CYP3A5 mRNA

PMID:12040753 PMID:12673034 PMID:15629111 PMID:15681896 PMID:19118567 More...

NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881

G

cytochrome P450, family 3, subfamily a, polypeptide 44

increases activity
multiple interactions

Rifampin results in increased activity of CYP3A4 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A4 protein; NR1I2 affects the reaction [Rifampin results in increased activity of CYP3A4 protein]

PMID:20361990 PMID:21224054

NCBI chr 5:145,710,793...145,742,701
Ensembl chr 5:145,710,793...145,742,684

G

cytochrome P450, family 4, subfamily a, polypeptide 10

multiple interactions
increases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A10 mRNA
Rifampin results in increased expression of CYP4A10 mRNA

PMID:21224054 PMID:27806127

NCBI chr 4:115,375,484...115,390,846
Ensembl chr 4:115,375,461...115,390,846

G

cytochrome P450, family 4, subfamily a, polypeptide 14

multiple interactions
increases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A14 mRNA
Rifampin results in increased expression of CYP4A14 mRNA

PMID:21224054 PMID:27806127

NCBI chr 4:115,343,397...115,353,355
Ensembl chr 4:115,343,397...115,353,339

G

cytochrome P450, family 7, subfamily a, polypeptide 1

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein
Rifampin results in decreased expression of CYP7A1 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA]

PMID:15629111 PMID:21127053 PMID:21224054 PMID:22258563 PMID:24259679 More...

NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633

G

cytochrome P450, family 8, subfamily b, polypeptide 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in decreased expression of CYP8B1 mRNA

NCBI chr 9:121,743,422...121,745,371
Ensembl chr 9:121,743,422...121,745,371

G

DDB1 and CUL4 associated factor 5

decreases expression

Rifampin results in decreased expression of DCAF5 mRNA

NCBI chr12:80,382,622...80,483,375
Ensembl chr12:80,382,622...80,483,375

G

DNA cross-link repair 1B

decreases expression

Rifampin results in decreased expression of DCLRE1B mRNA

NCBI chr 3:103,707,921...103,716,703
Ensembl chr 3:103,707,921...103,716,760

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of DDIT3 mRNA
Rifampin results in increased expression of DDIT3 mRNA; Rifampin results in increased expression of DDIT3 protein
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of DDIT3 mRNA]

PMID:21224054 PMID:27470132 PMID:32535746 PMID:33629115

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

24-dehydrocholesterol reductase

multiple interactions

[Rifampin results in increased activity of NR1I2 protein] which results in increased expression of DHCR24 mRNA

NCBI chr 4:106,418,279...106,446,310
Ensembl chr 4:106,418,235...106,446,310

G

deiodinase, iodothyronine, type I

increases expression

Rifampin results in increased expression of DIO1 mRNA

NCBI chr 4:107,148,662...107,164,365
Ensembl chr 4:107,148,662...107,164,366

G

distal-less homeobox 4

decreases expression

Rifampin results in decreased expression of DLX4 mRNA

NCBI chr11:95,031,273...95,037,116
Ensembl chr11:95,031,273...95,037,089

G

DnaJ heat shock protein family (Hsp40) member A1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA

NCBI chr 4:40,722,468...40,734,965
Ensembl chr 4:40,722,150...40,737,149

G

E2F transcription factor 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA

NCBI chr 2:154,401,320...154,411,812
Ensembl chr 2:154,401,327...154,411,812

G

endothelin 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of EDN1 mRNA

NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466

G

early growth response 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA

PMID:21127053 PMID:21224054

NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037

G

early growth response 2

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR2 mRNA

NCBI chr10:67,370,334...67,383,354
Ensembl chr10:67,371,305...67,378,018

G

early growth response 4

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR4 mRNA

NCBI chr 6:85,488,103...85,490,571
Ensembl chr 6:85,488,103...85,490,571

G

eukaryotic translation initiation factor 2 alpha kinase 3

increases phosphorylation
multiple interactions
increases expression

Rifampin results in increased phosphorylation of EIF2AK3 protein
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 protein]
Rifampin results in increased expression of EIF2AK3 mRNA; Rifampin results in increased expression of EIF2AK3 protein

PMID:24638036 PMID:27470132

NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229

G

eukaryotic translation initiation factor 2, subunit 1 alpha

increases phosphorylation

Rifampin results in increased phosphorylation of EIF2S1 protein

NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784

G

ELK1, member of ETS oncogene family

decreases expression

Rifampin results in decreased expression of ELK1 mRNA

NCBI chr X:20,799,634...20,816,847
Ensembl chr X:20,799,634...20,816,847

G

endothelial PAS domain protein 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of EPAS1 mRNA

NCBI chr17:87,061,292...87,140,838
Ensembl chr17:87,061,128...87,140,838

G

epoxide hydrolase 1, microsomal

increases expression
multiple interactions

Rifampin results in increased expression of EPHX1 mRNA
pimecrolimus inhibits the reaction [Rifampin results in increased expression of EPHX1 mRNA]

PMID:22258563 PMID:25313206 PMID:29356861

NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469

G

endoplasmic reticulum to nucleus signalling 1

multiple interactions
increases expression

Rifampin results in increased expression of and results in increased phosphorylation of ERN1 protein
Rifampin results in increased expression of ERN1 mRNA

NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678

G

ethanolamine phosphate phospholyase

increases expression

Rifampin results in increased expression of ETNPPL mRNA

NCBI chr 3:130,411,097...130,429,399
Ensembl chr 3:130,411,097...130,431,170

G

coagulation factor XIII, beta subunit

increases expression

Rifampin results in increased expression of F13B mRNA

NCBI chr 1:139,429,285...139,451,496
Ensembl chr 1:139,429,440...139,451,490

G

Fas cell surface death receptor

multiple interactions

Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]

PMID:11958592 PMID:12645856

NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172

G

Fas ligand

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA
Rifampin results in decreased expression of FASLG mRNA; Rifampin results in decreased expression of FASLG protein
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]

PMID:11958592 PMID:12645856 PMID:21224054 PMID:24552687

NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064

G

fatty acid synthase

increases expression
affects expression
multiple interactions

Rifampin results in increased expression of FASN mRNA
Rifampin affects the expression of FASN mRNA
pimecrolimus inhibits the reaction [Rifampin results in increased expression of FASN mRNA]

PMID:27806127 PMID:29356861 PMID:34689256

NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373

G

fibroblast growth factor 15

multiple interactions
increases expression

[Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA
Rifampin results in increased expression of FGF19 mRNA

NCBI chr 7:144,450,269...144,454,690
Ensembl chr 7:144,450,268...144,454,690

G

flavin containing monooxygenase 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA

NCBI chr 1:162,657,130...162,694,170
Ensembl chr 1:162,657,130...162,694,179

G

flavin containing monooxygenase 4

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA

NCBI chr 1:162,620,757...162,643,788
Ensembl chr 1:162,620,757...162,641,541

G

forkhead box A1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in decreased expression of FOXA1 mRNA

NCBI chr12:57,585,750...57,594,815
Ensembl chr12:57,587,414...57,593,702

G

forkhead box P1

increases expression

Rifampin results in increased expression of FOXP1 mRNA

NCBI chr 6:98,902,303...99,510,587
Ensembl chr 6:98,902,299...99,499,682

G

fucosyltransferase 1

decreases expression

Rifampin results in decreased expression of FUT1 mRNA

NCBI chr 7:45,266,862...45,270,483
Ensembl chr 7:45,266,713...45,270,483

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions
decreases expression
affects expression

[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]
Rifampin results in decreased expression of G6PC1 mRNA

PMID:24204015 PMID:34689256

NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729

G

growth arrest and DNA-damage-inducible 45 alpha

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA

NCBI chr 6:67,012,080...67,014,391
Ensembl chr 6:67,012,080...67,014,441

G

growth arrest and DNA-damage-inducible 45 beta

multiple interactions

NR1I2 protein promotes the reaction [Rifampin results in increased expression of GADD45B mRNA]

NCBI chr10:80,765,925...80,768,038
Ensembl chr10:80,765,907...80,768,038

G

GATA binding protein 5

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in decreased expression of GATA5 mRNA

NCBI chr 2:179,966,881...179,977,296
Ensembl chr 2:179,966,926...179,976,492

G

glucokinase

decreases expression
multiple interactions

Rifampin results in decreased expression of GCK protein
NR1I2 protein promotes the reaction [Rifampin results in decreased expression of GCK protein]

NCBI chr11:5,850,816...5,900,081
Ensembl chr11:5,850,820...5,900,081

G

GLIS family zinc finger 2

increases expression

Rifampin results in increased expression of GLIS2 mRNA

NCBI chr16:4,412,217...4,443,076
Ensembl chr16:4,412,577...4,442,788

G

predicted gene, 24031

decreases expression

Rifampin results in decreased expression of SNORA71C mRNA

NCBI chr14:26,218,810...26,218,940
Ensembl chr14:26,218,810...26,218,940

G

guanine nucleotide binding protein, alpha stimulating, olfactory type

decreases expression

Rifampin results in decreased expression of GNAL mRNA

NCBI chr18:67,221,369...67,359,863
Ensembl chr18:67,221,287...67,359,863

G

glutamic-oxaloacetic transaminase 1, soluble

multiple interactions
increases activity

[Rifampin co-treated with Isoniazid] results in increased activity of GOT1 protein
Rifampin results in increased activity of GOT1 protein

NCBI chr19:43,488,191...43,514,743
Ensembl chr19:43,488,191...43,513,044

G

glutamic pyruvic transaminase, soluble

multiple interactions
increases activity
increases expression

4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of GPT protein]; [Rifampin co-treated with Acetaminophen] results in decreased activity of GPT protein
Rifampin results in increased activity of GPT protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]
[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein; [Rifampin co-treated with Isoniazid] results in increased activity of GPT protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein]; Rifampin inhibits the reaction [Acetaminophen results in increased expression of GPT protein]

PMID:24685772 PMID:25886055 PMID:27470132 PMID:31678598 PMID:32633153 More...

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

glutathione peroxidase 2

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of GPX2 mRNA

PMID:21224054 PMID:33629115

NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273

G

glutathione peroxidase 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]

NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273

G

glutamate receptor, ionotropic, AMPA1 (alpha 1)

decreases expression

Rifampin results in decreased expression of GRIA1 mRNA

NCBI chr11:56,902,342...57,221,070
Ensembl chr11:56,902,213...57,221,070

G

glutathione reductase

increases activity

Rifampin results in increased activity of GSR protein

NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191

G

glutathione S-transferase, mu 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein

NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289

G

glutathione S-transferase, mu 5

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA

NCBI chr 3:107,803,240...107,806,002
Ensembl chr 3:107,803,137...107,806,002

G

glutathione S-transferase, pi 1

increases expression
multiple interactions

Rifampin results in increased expression of GSTP1 mRNA; Rifampin results in increased expression of GSTP1 protein
[Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 protein

NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985

G

glutathione S-transferase, theta 1

multiple interactions

GSTT1 gene polymorphism affects the susceptibility to [Isoniazid co-treated with Rifampin]; GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide]

PMID:18397238 PMID:20485159

NCBI chr10:75,619,647...75,634,418
Ensembl chr10:75,619,647...75,634,418

G

GTF2I repeat domain containing 2

increases expression

Rifampin results in increased expression of GTF2IRD2 mRNA

NCBI chr 5:134,211,629...134,246,988
Ensembl chr 5:134,212,858...134,253,209

G

granzyme B

increases secretion

Rifampin results in increased secretion of GZMB protein

NCBI chr14:56,496,293...56,499,791
Ensembl chr14:56,496,295...56,499,717

G

histocompatibility 2, class II antigen A, beta 1

affects expression

Rifampin affects the expression of HLA-DQB1 mRNA

NCBI chr17:34,482,201...34,488,392
Ensembl chr17:34,476,663...34,488,393

G

histocompatibility 2, class II, locus DMa

increases expression

Rifampin results in increased expression of HLA-DMA mRNA

NCBI chr17:34,338,667...34,358,075
Ensembl chr17:34,338,515...34,358,075

G

histocompatibility 2, M region locus 3

affects expression

Rifampin affects the expression of HLA-G mRNA

NCBI chr17:37,581,094...37,585,380
Ensembl chr17:37,581,111...37,585,375

G

heparin-binding EGF-like growth factor

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of HBEGF mRNA

NCBI chr18:36,637,980...36,648,858
Ensembl chr18:36,637,980...36,648,858

G

histone deacetylase 3

multiple interactions

Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]

NCBI chr18:38,070,024...38,088,073
Ensembl chr18:38,068,897...38,088,069

G

histone deacetylase 5

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in decreased expression of HDAC5 mRNA

NCBI chr11:102,085,244...102,120,968
Ensembl chr11:102,085,258...102,120,992

G

hairy/enhancer-of-split related with YRPW motif 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of HEY1 mRNA

NCBI chr 3:8,728,419...8,732,098
Ensembl chr 3:8,728,419...8,732,316

G

hepatocyte growth factor

multiple interactions

HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased abundance of Reactive Oxygen Species]; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]

NCBI chr 5:16,758,493...16,827,448
Ensembl chr 5:16,758,493...16,825,150

G

hypoxia inducible factor 1, alpha subunit

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

PMID:21127053 PMID:36878459

NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304

G

high-mobility group nucleosome binding domain 5

increases expression

Rifampin results in increased expression of HMGN5 mRNA

NCBI chr X:108,048,143...108,056,986
Ensembl chr X:108,048,140...108,057,010

G

heme oxygenase 1

multiple interactions
increases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA
dorsomorphin inhibits the reaction [Rifampin results in increased expression of HMOX1 protein]
Rifampin results in increased expression of HMOX1 mRNA; Rifampin results in increased expression of HMOX1 protein
[arsenite co-treated with Rifampin] results in increased expression of HMOX1 mRNA

PMID:21224054 PMID:22159698 PMID:22258563 PMID:31678598

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

hepatic nuclear factor 4, alpha

multiple interactions

[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein]

PMID:21127053 PMID:21292004 PMID:21764778 PMID:25069801

NCBI chr 2:163,348,731...163,414,827
Ensembl chr 2:163,348,728...163,414,830

G

histamine receptor H1

increases expression

Rifampin results in increased expression of HRH1 mRNA

NCBI chr 6:114,374,897...114,459,432
Ensembl chr 6:114,374,897...114,460,257

G

heat shock protein 1-like

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA

NCBI chr17:35,191,679...35,198,204
Ensembl chr17:35,191,679...35,198,261

G

heat shock protein 5

multiple interactions
increases expression

ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein]
[Rifampin co-treated with Cobicistat] results in increased expression of HSPA5 mRNA
Rifampin results in increased expression of HSPA5 mRNA; Rifampin results in increased expression of HSPA5 protein
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 protein]

PMID:24638036 PMID:27470132 PMID:32535746 PMID:33629115

NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559

G

heat shock protein 8

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA

NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383

G

heat shock protein 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA

NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417

G

heat shock protein 1 (chaperonin)

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA

NCBI chr 1:55,116,992...55,127,402
Ensembl chr 1:55,116,994...55,127,402

G

heat shock protein 1 (chaperonin 10)

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA

NCBI chr 1:55,127,307...55,130,476
Ensembl chr 1:55,127,291...55,130,466

G

interferon gamma

increases secretion

Rifampin results in increased secretion of IFNG protein

NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797

G

insulin-like growth factor binding protein 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP1 mRNA

NCBI chr11:7,147,787...7,152,546
Ensembl chr11:7,147,782...7,152,546

G

insulin-like growth factor binding protein 3

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP3 mRNA

NCBI chr11:7,156,086...7,165,498
Ensembl chr11:7,156,086...7,163,923

G

insulin-like growth factor binding protein 4

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP4 mRNA

NCBI chr11:98,930,820...98,943,481
Ensembl chr11:98,932,070...98,945,218

G

interleukin 10

affects expression

Rifampin affects the expression of IL10 protein

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 12 receptor, beta 2

decreases expression

Rifampin results in decreased expression of IL12RB2 mRNA

NCBI chr 6:67,263,914...67,353,277
Ensembl chr 6:67,268,302...67,353,172

G

interleukin 13

increases secretion

Rifampin results in increased secretion of IL13 protein

NCBI chr11:53,522,150...53,525,529
Ensembl chr11:53,522,151...53,525,529

G

interleukin 18

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA

NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140

G

interleukin 1 beta

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; Rifampin inhibits the reaction [Rotenone results in increased expression of and results in increased secretion of IL1B protein]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]
Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]
Rifampin results in decreased expression of IL1B mRNA; Rifampin results in decreased expression of IL1B protein

PMID:21224054 PMID:25051504 PMID:26086368 PMID:31648047

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

decreases expression
multiple interactions
increases expression

Rifampin results in decreased expression of IL6 protein
Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA]
Rifampin results in increased expression of IL6 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA

PMID:21224054 PMID:21357946 PMID:25051504 PMID:31648047

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

INO80 complex subunit D

decreases expression

Rifampin results in decreased expression of INO80D mRNA

NCBI chr 1:63,086,960...63,153,693
Ensembl chr 1:62,997,577...63,153,849

G

insulin II

multiple interactions

INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]
Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein]

PMID:24204015 PMID:33412187

NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118

G

integrator complex subunit 6

decreases expression

Rifampin results in decreased expression of INTS6 mRNA

NCBI chr14:62,913,774...62,998,617
Ensembl chr14:62,913,779...62,998,618

G

IQ motif containing with AAA domain 1

decreases expression

Rifampin results in decreased expression of IQCA1 mRNA

NCBI chr 1:89,969,854...90,081,158
Ensembl chr 1:89,969,854...90,081,123

G

integrin, beta-like 1

decreases expression

Rifampin results in decreased expression of ITGBL1 mRNA

NCBI chr14:123,897,331...124,215,173
Ensembl chr14:123,897,383...124,213,030

G

jun proto-oncogene

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of JUN mRNA

NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459

G

kirre like nephrin family adhesion molecule 3

decreases expression

Rifampin results in decreased expression of KIRREL3 mRNA

NCBI chr 9:34,396,850...34,952,103
Ensembl chr 9:34,397,190...34,948,012

G

Kruppel-like transcription factor 2 (lung)

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF2 mRNA

NCBI chr 8:73,072,906...73,075,498
Ensembl chr 8:73,072,877...73,075,500

G

Kruppel-like transcription factor 5

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF5 mRNA

NCBI chr14:99,536,127...99,550,848
Ensembl chr14:99,536,127...99,552,472

G

Kruppel-like transcription factor 6

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF6 mRNA

NCBI chr13:5,911,488...5,920,392
Ensembl chr13:5,911,481...5,920,393

G

low density lipoprotein receptor

increases expression

Rifampin results in increased expression of LDLR mRNA

NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215

G

left right determination factor 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of LEFTY1 mRNA

NCBI chr 1:180,762,587...180,765,966
Ensembl chr 1:180,762,587...180,765,965

G

leptin

increases expression

Rifampin results in increased expression of LEP protein

NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876

G

leukocyte tyrosine kinase

increases expression

Rifampin results in increased expression of LTK mRNA

NCBI chr 2:119,581,807...119,590,912
Ensembl chr 2:119,581,801...119,590,912

G

v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian)

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of MAFF mRNA

NCBI chr15:79,230,813...79,243,278
Ensembl chr15:79,230,821...79,243,276

G

microtubule-associated protein 1 light chain 3 beta

decreases metabolic processing
multiple interactions
increases lipidation

Rifampin results in decreased metabolism of MAP1LC3B protein
ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [Rifampin results in increased lipidation of MAP1LC3B protein]; Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]

PMID:29908302 PMID:31648047

NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499

G

mitogen-activated protein kinase 8

multiple interactions

Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]]; Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]

NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115

G

MAP kinase-activated protein kinase 2

increases phosphorylation

Rifampin results in increased phosphorylation of MAPKAPK2 protein

NCBI chr 1:130,981,437...131,025,580
Ensembl chr 1:130,981,437...131,025,563

G

microtubule-associated protein, RP/EB family, member 3

increases expression

Rifampin results in increased expression of MAPRE3 mRNA

NCBI chr 5:30,972,075...31,023,447
Ensembl chr 5:30,971,985...31,023,450

G

matrilin 2

increases expression

Rifampin results in increased expression of MATN2 mRNA

NCBI chr15:34,306,827...34,436,388
Ensembl chr15:34,306,823...34,436,419

G

myelin basic protein

affects expression

Rifampin affects the expression of MBP mRNA

NCBI chr18:82,492,883...82,603,762
Ensembl chr18:82,493,271...82,603,762

G

myeloid cell leukemia sequence 1

multiple interactions

[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein

NCBI chr 3:95,564,017...95,583,553
Ensembl chr 3:95,566,099...95,570,487

G

transformed mouse 3T3 cell double minute 2

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA

NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663

G

mediator complex subunit 1

multiple interactions
decreases expression

Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein]
Rifampin results in decreased expression of MED1 mRNA

PMID:21292004 PMID:22214767 PMID:24552687

NCBI chr11:98,042,980...98,084,121
Ensembl chr11:98,042,980...98,084,119

G

multiple inositol polyphosphate histidine phosphatase 1

increases expression

Rifampin results in increased expression of MINPP1 mRNA

NCBI chr19:32,463,169...32,492,770
Ensembl chr19:32,463,169...32,492,764

G

microRNA 143

increases expression

Rifampin results in increased expression of MIR143 mRNA

NCBI chr18:61,782,267...61,782,329
Ensembl chr18:61,782,267...61,782,329

G

microRNA 145a

increases expression

Rifampin results in increased expression of MIR145 mRNA

NCBI chr18:61,780,896...61,780,965
Ensembl chr18:61,780,896...61,780,965

G

microRNA 148b

decreases expression

Rifampin results in decreased expression of MIR148B mRNA

NCBI chr15:103,193,552...103,193,648
Ensembl chr15:103,193,552...103,193,648

G

microRNA 149

decreases expression

Rifampin results in decreased expression of MIR149 mRNA

NCBI chr 1:92,778,100...92,778,165
Ensembl chr 1:92,778,100...92,778,165

G

microRNA 15b

increases expression

Rifampin results in increased expression of MIR15B mRNA

NCBI chr 3:68,917,105...68,917,168
Ensembl chr 3:68,917,105...68,917,168

G

microRNA 186

multiple interactions

[Isoniazid co-treated with Rifampin] results in increased expression of MIR186 mRNA

NCBI chr 3:157,249,916...157,249,986
Ensembl chr 3:157,249,916...157,249,986

G

microRNA 192

decreases expression

Rifampin results in decreased expression of MIR192 mRNA

NCBI chr19:6,314,874...6,314,962
Ensembl chr19:6,314,874...6,314,962

G

microRNA 200a

increases expression

Rifampin results in increased expression of MIR200A mRNA

NCBI chr 4:156,139,353...156,139,442
Ensembl chr 4:156,139,353...156,139,442

G

microRNA 202

increases expression

Rifampin results in increased expression of MIR202 mRNA

NCBI chr 7:139,537,602...139,537,673
Ensembl chr 7:139,537,602...139,537,673

G

microRNA 204

increases expression

Rifampin results in increased expression of MIR204 mRNA

NCBI chr19:22,727,969...22,728,036
Ensembl chr19:22,727,969...22,728,036

G

microRNA 20b

increases expression

Rifampin results in increased expression of MIR20B mRNA

NCBI chr X:51,830,990...51,831,069
Ensembl chr X:51,830,990...51,831,069

G

microRNA 212

decreases expression

Rifampin results in decreased expression of MIR212 mRNA

NCBI chr11:75,064,214...75,064,304
Ensembl chr11:75,064,214...75,064,304

G

microRNA 215

increases expression

Rifampin results in increased expression of MIR215 mRNA

NCBI chr 1:185,045,778...185,045,889
Ensembl chr 1:185,045,778...185,045,889

G

microRNA 21a

increases expression

Rifampin results in increased expression of MIR21 mRNA

NCBI chr11:86,474,893...86,474,984
Ensembl chr11:86,474,893...86,474,984

G

microRNA 22

increases expression

Rifampin results in increased expression of MIR22 mRNA

NCBI chr11:75,354,542...75,354,636
Ensembl chr11:75,354,542...75,354,636

G

microRNA 26b

increases expression

Rifampin results in increased expression of MIR26B mRNA

NCBI chr 1:74,433,469...74,433,553
Ensembl chr 1:74,433,469...74,433,553

G

microRNA 295

multiple interactions

[Isoniazid co-treated with Rifampin] results in increased expression of MIR295 mRNA; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of MIR295 mRNA]

NCBI chr 7:3,269,447...3,269,515
Ensembl chr 7:3,269,447...3,269,515

G

microRNA 296

decreases expression

Rifampin results in decreased expression of MIR296 mRNA

NCBI chr 2:174,108,840...174,108,918
Ensembl chr 2:174,108,840...174,108,918

G

microRNA 29a

decreases expression

Rifampin results in decreased expression of MIR29A mRNA

NCBI chr 6:31,039,595...31,039,682
Ensembl chr 6:31,039,595...31,039,682

G

microRNA 31

increases expression

Rifampin results in increased expression of MIR31 mRNA

NCBI chr 4:88,828,794...88,828,899
Ensembl chr 4:88,828,794...88,828,899

G

microRNA 328

increases expression

Rifampin results in increased expression of MIR328 mRNA

NCBI chr 8:106,034,996...106,035,092
Ensembl chr 8:106,034,996...106,035,092

G

microRNA 340

increases expression

Rifampin results in increased expression of MIR340 mRNA

NCBI chr11:49,960,529...49,960,626
Ensembl chr11:49,960,529...49,960,626

G

microRNA 34a

decreases expression

Rifampin results in decreased expression of MIR34A mRNA

NCBI chr 4:150,152,911...150,153,012
Ensembl chr 4:150,152,911...150,153,012

G

microRNA 362

decreases expression

Rifampin results in decreased expression of MIR362 mRNA

NCBI chr X:7,108,221...7,108,285
Ensembl chr X:7,108,221...7,108,285

G

microRNA 374b

increases expression

Rifampin results in increased expression of MIR374B mRNA

NCBI chr X:102,616,666...102,616,760
Ensembl chr X:102,616,666...102,616,760

G

microRNA 532

decreases expression

Rifampin results in decreased expression of MIR532 mRNA

NCBI chr X:7,114,641...7,114,736
Ensembl chr X:7,114,641...7,114,736

G

microRNA 539

increases expression

Rifampin results in increased expression of MIR539 mRNA

NCBI chr12:109,694,563...109,694,636
Ensembl chr12:109,694,563...109,694,636

G

microRNA 652

decreases expression

Rifampin results in decreased expression of MIR652 mRNA

NCBI chr X:141,521,996...141,522,093
Ensembl chr X:141,521,996...141,522,093

G

microRNA 874

decreases expression

Rifampin results in decreased expression of MIR874 mRNA

NCBI chr13:58,170,939...58,171,014
Ensembl chr13:58,170,939...58,171,014

G

microRNA let7e

increases expression

Rifampin results in increased expression of MIRLET7E mRNA

NCBI chr17:18,050,614...18,050,706
Ensembl chr17:18,050,614...18,050,706

G

antigen identified by monoclonal antibody Ki 67

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein

NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090

G

matrix metallopeptidase 3

decreases secretion

Rifampin results in decreased secretion of MMP3 protein

NCBI chr 9:7,445,845...7,455,975
Ensembl chr 9:7,445,822...7,455,975

G

myeloperoxidase

multiple interactions

Rifampin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

major histocompatibility complex, class I-related

affects expression

Rifampin affects the expression of MR1 mRNA

NCBI chr 1:155,003,620...155,022,560
Ensembl chr 1:155,003,023...155,022,560

G

microsomal triglyceride transfer protein

decreases expression

Rifampin results in decreased expression of MTTP mRNA

NCBI chr 3:137,795,616...137,849,179
Ensembl chr 3:137,795,615...137,850,729

G

myosin, heavy polypeptide 6, cardiac muscle, alpha

increases expression

Rifampin results in increased expression of MYH6 mRNA

NCBI chr14:55,179,378...55,205,553
Ensembl chr14:55,179,378...55,204,384

G

nuclear assembly factor 1 ribonucleoprotein

decreases expression

Rifampin results in decreased expression of NAF1 mRNA

NCBI chr 8:67,312,594...67,343,216
Ensembl chr 8:67,312,869...67,343,216

G

nucleosome assembly protein 1-like 5

increases expression

Rifampin results in increased expression of NAP1L5 mRNA

NCBI chr 6:58,882,218...58,884,111
Ensembl chr 6:58,882,218...58,884,061

G

nuclear receptor coactivator 1

multiple interactions

Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Miconazole promotes the reaction [Rifampin results in increased expression of NCOA1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]

PMID:11581012 PMID:12072427 PMID:16819505 PMID:17088262 PMID:17438109 More...

NCBI chr12:4,297,362...4,569,452
Ensembl chr12:4,297,362...4,527,182

G

nuclear receptor coactivator 2

multiple interactions

Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein]

NCBI chr 1:13,209,329...13,444,451
Ensembl chr 1:13,209,329...13,444,307

G

nuclear receptor coactivator 6

multiple interactions

NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]

NCBI chr 2:155,232,585...155,315,741
Ensembl chr 2:155,232,576...155,315,814

G

nuclear receptor co-repressor 1

multiple interactions

Rifampin inhibits the reaction [NCOR1 protein binds to and results in decreased activity of NR1I2 protein]

NCBI chr11:62,207,132...62,348,200
Ensembl chr11:62,207,252...62,349,367

G

nuclear receptor co-repressor 2

multiple interactions

[NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein]

PMID:12072427 PMID:22214767 PMID:25313206 PMID:26883953 PMID:28289823 More...

NCBI chr 5:125,094,217...125,256,302
Ensembl chr 5:125,094,217...125,256,283

G

nuclear factor, erythroid derived 2, like 2

increases expression
multiple interactions
decreases expression
decreases activity

Rifampin results in increased expression of NFE2L2 protein
[tanshinone co-treated with Rifampin] results in increased expression of NFE2L2 mRNA; tanshinone inhibits the reaction [Rifampin results in decreased expression of NFE2L2 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of NFE2L2 protein]
Rifampin results in decreased expression of NFE2L2 mRNA; Rifampin results in decreased expression of NFE2L2 protein
Rifampin results in decreased activity of NFE2L2 protein
Rifampin inhibits the reaction [arsenite results in increased activity of NFE2L2 protein]

PMID:31678598 PMID:33307820 PMID:33412187

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nuclear transcription factor-Y alpha

decreases expression

Rifampin results in decreased expression of NFYA mRNA

NCBI chr17:48,693,917...48,716,782
Ensembl chr17:48,693,913...48,716,934

G

NLR family, pyrin domain containing 3

multiple interactions

Rifampin inhibits the reaction [Rotenone results in increased expression of NLRP3 protein]

NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782

G

nitric oxide synthase 2, inducible

multiple interactions
increases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA
Rifampin results in increased expression of NOS2 mRNA

PMID:21224054 PMID:24552687

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

neuronal PAS domain protein 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of NPAS1 mRNA

NCBI chr 7:16,189,643...16,210,741
Ensembl chr 7:16,189,646...16,211,653

G

natriuretic peptide type B

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of NPPB mRNA

NCBI chr 4:148,070,264...148,071,662
Ensembl chr 4:148,070,245...148,071,662

G

nuclear receptor subfamily 0, group B, member 2

increases expression
decreases expression

Rifampin results in increased expression of NR0B2 mRNA
Rifampin results in decreased expression of NR0B2 mRNA

PMID:15670600 PMID:34689256

NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

NR1H3 mutant form inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]

NCBI chr 2:91,014,406...91,033,189
Ensembl chr 2:91,014,406...91,033,179

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4

NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447

G

nuclear receptor subfamily 1, group I, member 2

affects response